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CHAPTER I 
Clinical pharmacology of naproxen-sodium and diflunisal: 
introduction and problem statements 

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND RHEUMATOID ARTHRITIS 
Non-steroidal anti-inflammatory drugs (NSAID) have an important 
place in the pharmacotherapeutic approach to rheumatoid arthritis 
(RA). In what is imdicated as the first phase of stepwise management 
of the disease (phase I = "control of symptoms") they reduce disease 
activity in some patients to a level where no need for long-term 
therapy with "specific" drugs exists. In clinical practice the 
patient's condition is reviewed, in mild cases, after maximally six 
months of this symptomatic therapy. When the disease is not adequate-
ly controlled despite optimal anti-inflammatory therapy, or when 
progressive disease exists, phase II (= "control of disease") treat-
ment is started. 
In patients with signs of poor prognosis for spontaneous 
remission or improvement (such as serious anaemia, vasculitis, 
rheumatoid nodules and a high titre in serological tests for 
rheumatoid factor) the first phase of treatment should last only 
a few weeks to months. In these cases phase II treatment is started 
earlier, or at once and the individual's preference for one out of a 
series of NSAID ( a decision process to be specified in the next 
paragraph) is determined during phase II. In phase II treatment of 
RA, NSAID do retain their place: they provide continued symptomatic 
relief inaddition to major antirheumatic drug's effect. For an out-
line of this phase I/II schedule of the pharmacotherapeutic approach 
to RA patients we refer to Huskisson's contribution in the theme vo-
lume of the Clinics in Rheumatic Diseases "Antirheumatic Drugs" 
(1). 
In the case of freshly started NSAID treatment the drug serves 
a twofold purpose: a rapid symptomatic influence on complaints and 
symptoms (pain, stiffness) on the one hand, and a gradual reduction 
of disease activity on the other. The later effect may implicate 
that milder second-line therapy (or none at all) proves to be 
necessary in striking the balance after the period mentioned. The 
number of NSAID on the market is amazingly large (more than thirty!). 
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Apart from commercial considerations this number, and the development 
of new drugs, are at least partly justified by the enormous interin-
dividual differences in the response of RA patients to NSAID treat-
ment. If in an individual a drug is insuccessful after, say, a two-
week trial, then the next drug or a different type of drug may be 
effective. Huskisson et al. (2) showed that exposure of a group of 
patients to four propionic acid derivatives led to useful changes 
in treatment in nearly 50%, and that finally 60% experienced adequate 
symptomatic relief upon one of the four drugs studied. Data of this 
type support the strategy of treating patients in the early phase of 
disease with a series of different NSAID until an effective or the 
most effective drug for the individual is found. There is no theo-
retical explanation for the marked difference in individual res-
ponses/preferences, and only the experience gained in clinical 
practice therefore dictates the logic of trying a number of drugs in 
succession (3). Studies comparing the prescribing practice of rheuma-
tologists in two countries (Norway and The Netherlands) suggest that 
some 10-15 NSAID are in fact needed in order to provide a reasonable 
choice (4) for common rheumatic conditions. About 10% of patients do 
not respond favourably to any of the currently available drugs (2). 
CLINICAL TRIALS WITH NEW NSAID 
The analgesic and anti-inflammatory effect of NSAID becomes mani-
fest after a few hours, and attains its maximum within a few days ac-
cording to literature (1). The effectiveness of drugs of this class 
is therefore concluded from results of short-term trials (1-2 weeks' 
duration) . Since NSAID are in practice prescribed for months or 
years, long-term trials are also essential, to determine: 
- whether the efficacy is maintained, and 
- the type and incidence of adverse effects which occur during long-
term treatment . 
A plea for long-term trails has recently been made by the EULAR 
Standing Committee on International Clinical Studies, including 
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Drug Control (5). 
In this context the adjective "long-term" stands for the abovemen-
tioned time-span of about six months. In the case of a non-aggressive 
clinical picture and course of disease, an investigator is entitled 
to expose a patient to experimental NSAID treatment for this period. 
In a disease, such as RA with sometimes so capricious a course, a 
cross-over design is unsuitable for long term studies. A double-
blind design is obligatory, because most assessment parameters are 
subjective or partly subjective. 
A review of the immense literature on "the clinical trial", and 
more specifically on the clinical trial in RA, would exceed the 
scope of this presentation. Excellent publications on these topics 
are readily accessible. For the sake of convenience a few authors 
are mentioned. 
Clinical trials in general: 
Harris and Fitzgerald 1970 (6) 
Jouhar and Grayson 1973 (7) 
Hamilton 1974 (8) 
McMahon 1974 (9) 
Good 1976 (10) 
Johnson and Johnson 1977 (11) 
Clinical trials in Rheumatology: 
Katona and Blengio 1975 (12) 
Lee and Carson Dick 
Arrigoni-Martelli 
Dumonde and Jasani 
Fehr et al. (EULAR) 
Feltkamp and Van der 
Korst 
Holt 
Lequesne (EULAR) 
Paulus et al. 
1976 
1978 
1978 
1978 
1979 
1979 
1980 
1981 
(13) 
(14) 
(15) 
(16) 
(17) 
(18) 
(5) 
(19) 
CHOICE OF INVESTIGATIONAL DRUGS 
Acetyl salicylic acid is the most commonly used anti-inflammatory 
analgesic drug, and it is the standard against which all other NSAID 
are measured in many respects. Its usefulness for patients suffering 
from RA has been demonstrated in the mid-Sixties by the studies of 
Fremont-Smith and Bayles (1965), and of Boardman and Hart (1967) 
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(20, 21). Anglo-ameri can authorities (1, 3, 22, 23, ?4, 25, 26, 27, 
28, 29) consider salicylates to be the drugs of first choice in the 
NSAID treatment of RA. Their side effects, however, are substantial; 
one-third of the patients find full doses unacceptable on account of 
dyspepsia (30); and they also cause acute gastrointestinal 
haemorrhage and central nervous system problems. In addition there 
is some doubt whether the advice to start RA treatment with salicy-
lates - complicated by the necessity of plasma level monitoring -
is followed by the medical profession now that alternatives have 
become available. One of the authors (1) endorses as "sensible" the 
therapeutic policy of many physicians who give propionic acid deri-
vatives first in view of the disadvantages of salicylic acid. 
In view the special place of salicylates, we decided nevertheless 
to study the usefulness of the salicylic acid derivative diflunisal 
in RA patients, as a drug with possibly greater potency and fewer 
side effects than acetylsalicylic acid. Aspects of the pharmaco-
kinetics of this drug had been studied in Nijmegen in volunteers 
(31). Its value in the treatment of patients with RA had not been 
previously studied (32). 
Naproxen was chosen as the reference drug because it is an 
"established" NSAID. The value of this drug has been reviewed by the 
same group of authors (33). Its sodium salt was thought (34) to act 
more promptly and intensively. 
Both drugs were given in doses which, lege artis, were sufficient 
(5); this indicates a dose level of diflunisal at which the drug 
shows anti-inflammatory activity. Paracetamol was chosen as rescue 
analgesic; the patients had to register their need for additional. 
analgesia during the study. 
PROBLEM STATEMENTS 
Clinical trial of two NSAID 
The aim of the study was to compare two NSAID, diflunisal and 
naproxen sodium, in a double-blind 24-week clinical trial in patients 
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with RA, using current parameters. 
Problem statements specified 
We elaborated this competitive evaluation differently and to some 
extent more in depth on a number of points. These refinements 
concerned: 
1. The possible correlation, within the individuals, between the 
value of the parameters of disease activity at the beginning of 
the trial period ana their value at its end: is their reduction 
an absolute figure or a fraction of the initial value? 
2. The merits of the (long-term) trial period, to be concluded from 
the comparison with the built-in short-term "trial" (apart from 
the long-term trial's right to exist as a representation of the 
situation in real life): after what time do the two drugs produce 
their maximal effect, do they both keep their level of efficacy, 
are differences temporary, etc? 
3. The merits of the parameters used as indices of disease activity: 
are they correct numerical representations of the reality under 
study? Are their changes during treatment correlated? Is any 
parameter superior, or should another one be rejected, possibly 
because of poor correlation with the others? 
4. Statistical questions: 
- Is it allowed and possible - in the case of an unexpectedly 
marked difference between the two groups upon entry into the 
trial - to correct for initial differences, and would this cor-
rection provide stronger evidence for conclusions? 
- Is an over-all assessment of the two pharmacotherapies on the 
basis of multivariate analysis allowed, possible and useful? 
5. Pharmacokinetic questions: 
- Do assessments of drug levels provide some estimate of drug 
compliance? 
Do these measurements give an impression of the pharmacokinetics 
of the two drugs in chronic use? 
For most NSAID, kinetic data on chronic medication are com-
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pletely lacking; moreover, the pharmacokinetics of both drugs under 
study are special. For salicylates marked interindividual differences 
between rheumatoid patients have been found (35); the salicylates 
are subject to mixed-order kinetics (capacity-limited elimination) 
(36), and so is diflunisal (31); finally, a tendency of serum sali-
cylate concentrations to fall has been demonstrated after prolonged 
administration, perhaps due to hepatic enzyme induction (37, 38). 
In the case of naproxen, the serum protein-binding capacity plays 
a role: above a certain level, enlargement of the dose causes a 
disproportionally great increase in free, i.e. unbound drug in the 
plasma as well as increased elimination by renal excretion (39). 
6. Hypouricaemic and uricosuric effect: do one or both of the drugs 
have an effect on uric acid handling (the question is particular-
ly relevant to diflunisal, in view of the wellknown potent urico-
suric effect of salicylic acid (40). 
7. Drug interaction: the groups of patients did not comprise suf-
ficiently large numbers receiving concomitant treatment with 
antacids, laxatives, antimicrobials, or given to alcohol abuse; 
a study in volunteers therefore was undertaken of the (short-term) 
combined medication with diflunisal and amoxycillin: due to 
interaction, failure of treatment of infection, break-down of 
analgesia, or toxic effects from relative diflunisal overdose 
might be feared. 
8. Suggestions for trial optimalization: 
- Would it be possible to define more strictly the criteria for 
admission/exclusion of patients on account of disease 
activity (in addition to the majority of the usual criteria 
concerning aspects not related to RA)? 
- Would it be advisable to analyse all patients together in the 
course of a trial (without breaking the double-blind code), 
thus making it possible to stop the trial in due course because 
of insufficient activity of a new drug (given a predictable 
response to be expected from the reference drug)? 
- Could measurement of plasma levels of drugs during the trial 
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(without breaking the code: renaming of the samples by an outsi-
der) be advised, in order to verify compliance at the right 
moment and to prevent accumulation of analytical work at the end 
of the blind period? 
9. Relation between pharmacokinetics and pharmacodynamics: 
Is there any correlation between drug levels and clinical data 
(good therapeutic response, failure, side effects)? 
10.Side effects: would it be possible to suspect or to recognize a 
profile (41, 42) of side effects, despite the rather limited num-
bers of patients studied? Could or should a procedure be drafted 
when side effects would produce a considerable number of drop-
outs? How should the data obtained in the other patients be 
valued? 
The results of our study are presented in the subsequent chapters 
of this thesis. 
In the final chapter the problem statement of the comparison of 
diflunisal and naproxen sodium is discussed once more, adding some 
supplementary conclusions. The ten abovementioned questions will be 
discussed point by point. 
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CHAPTER II 
Rapid high-performance liquid chromatographic method for the 
quantitative determination of diflunisal in plasma 
J.W.A. van Loenhout, H.C.J. Ketelaars, F.W.J. Gribnau, 
C.A.M. van Ginneken and Y. Tan 
This chapter was published in "Journal of Chromatography, 
Biomedical Applications", 182 (1980) 487-491 
19 

INTRODUCTION 
Diflunisal {5(2'4'-difluorophenyl)salicylic acid) is a new 
ring-substituted salicylic acid derivative with promising anal­
gesic and anti-inflammatory properties which make the drug useful 
for the treatment of osteoarthritis (1, 2). Recent studies (3, 4, 
5) indicate that the drug exhibits a dose-dependent pharmaco­
kinetic profile. As compared to other salicylates diflunisal has 
a long plasma half-life time which, similarly to salicylic acid 
itself (6), increases with increasing dose. This rather long Ц is 
especially relevant since it permits a dosage regimen with only 
one or two daily doses. On the other hand the capacity limited 
elimination rate implicates the necessity of monitoring plasma 
drug levels for the establishment of optimal dosage regimens. 
For the assay of drug levels in the course of a clinical 
pharmacological study comparing the therapeutic efficacies of 
diflunisal and of naproxen, a rapid and specific assay method for 
these drugs was needed. 
In this report a description of a high-performance liquid 
chromatographic (HPLC) method for the determination of diflunisal 
is given, which combines a short-time analysis with ease of hand­
ling. The procedure is based upon almost quantitative extraction 
of the diflunisal from plasma followed by reversed-phase liquid 
chromatography with UV spectrophotometric detection. As an intern­
al standard the analgesic naproxen (6-methoxy-a-methyl-2-
naphtalene-acetic acid) is used. This method has several advan­
tages in comparison with published procedures involving spectro-
fluorometry (4) and has been already applied in preliminary 
pharmacokinetic studies. 
MATERIALS AND METHODS 
Materials 
Diflunisal, a pure substance for reference purposes, was kind-
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ly provided by Merck, Sharp and Dohme (Brussels, Belgium) and 
naproxen by Syntex (Palo Alto, CA, U.S.A.). 
The column-filling material, LiChrosorb RP-8 (5 μιτι) was obtain­
ed from Merck (Darmstadt, G.F.R.) and the tetramethylammoni urn 
hydrogen sulphate, used as a counter-ion, from Fluka (Buchs, 
Switserland). All other reagents were analytical grade products 
from Merck. The diethyl ether was distilled shortly before use. 
Stock solutions of diflunisal and naproxen were prepared by 
dissolving 25 mg of either drug in 100 ml of methanol. 
Apparatus 
A Hewlett-Packard 1084B high-pressure liquid Chromatograph 
equipped with an autosampler and a HP 79850 LC terminal was used 
(Hewlett-Packard, Waldbronn, G.F.R.). The column (stainless steel, 
15 cm χ 0.46 cm I.D.) was packed with LiChrosorb RP-8 (5 urn) and 
eluted with a methanol-water mixture (50:50), containing 0.01 M 
tetramethyl ammoni um hydrogen sulphate and Tris {tns(hydroxy-
methyl)aminomethane}. The apparatus was operated at a column 
temperature of 32 С and a flow-rate of 1.4 ml/min. The column 
pressure was 26 · 10 3 KPa. The eluting compounds were detected 
and measured at 254 nm. 
Extraction 
Plasma (0.5 ml) containing diflunisal, is pipetted into a test 
tube provided with a screw-cap. Naproxen (50 yg) in methanolic 
solution (0.2 ml) is added. After thourough mixing on a whirl-
mixer 5 ml of a diethyl ether-n-hexane (50:50) mixture and 0.7 ml 
of a 1.5 N hydrochloric acid solution are added. The closed tube 
is mechanically shaken for 30 min and then centri fuged for 15 min 
at 1500 g. The organic layer is transferred into another test 
tube and evaporated to dryness at 30 С under a gentle stream of 
dry, filtered air. The residu is taken up into 1 ml of methanol 
of which 10 yl are injected into the liquid Chromatograph. 
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Calibration and recovery 
The procedure is calibrated by programming the LC terminal in 
the internal standard. Various known amounts of diflunisal and a 
fixed amount of naproxen (50 mg/1) are added to blank plasma. 
These samples are analysed as outlined above and calibration 
graphs are obtained by plotting the concentration of diflunisal 
calculated by the terminal (from integration of the signal) 
against the concentration added, assuming a linear relation 
between the surfaces under the curves of the different diflunisal 
concentrations and the 100 mg/1 concentration as a reference. 
The overall recovery of the procedure is determined by 
comparison of the values obtained after extraction with values 
obtained after direct injection of standard solutions. 
RESULTS AND DISCUSSION 
Under the conditions employed no interferences by endogenous 
plasma constituents occurred in the chromatogram. For example, 
Fig. 1 shows a chromatogram obtained from blank plasma as well 
as one from plasma containing diflunisal and naproxen. A whole 
run is completed within 10 min, the retention times of naproxen 
and diflunisal being about 2.5 and 4.2 min respectively. 
Linear calibration curves were obtained over the concentration 
range of 5-100 mg/1 of diflunisal in plasma. The limit of detection 
diflunisal with the method described is substantially below 
5 mg/1, but in order to obtain reproducible, quantitative results 
at such low concentrations a separate calibration has to be 
performed. The deviation from linearity in the very low 
concentration range is causea by a slight tailing of the 
diflunisal peak which leads to a certain loss of signal in the 
automatic integration procedure. In the low concentration level 
(9.936 mg/1) the detected concentration was 9.06 mg/1 with an 
absolute error -0.88 mg/1, the relative error -8.85%. In the high 
concentration level 99.36 mg/1 the detected concentration was 
98.60 mg/1 with an absolute error of -0.76cmq/l, the relative error 
- 0,76%. On the other hand, 
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for practical purposes it is not necessary to extend the 
diflunisal assay to such low concentrations since therapeutic 
plasma levels probably exceed the 10 mg/1 concentration. 
HPLC chromatogram 
blanc plasma 
О 2 4 6 B 10 mm 
retention time 
plasma containing 
A > паргокеп 
В* diflunisal 
0 2 4 6 в Ю mm 
retention time 
Fig.l. Chromatogram of (left) blank plasma and (right) plasma 
containing diflunisal (50 mg/1) and naproxen (100 mg/1). 
Retentions times: naproxen (A) 2.55 min, diflunisal (B) 4.11 min. 
The overall recovery of the extraction of diflunisal from 
the plasma in this procedure is almost complete. Over the entire 
concentration range studied it is 96% on average, without any 
systematic changes. 
Upon repeated measurement (10 assays) of two samples, one in 
the low concentration level (9.936 mg/1) and one in the high 
concentration level (99.36 mg/1), a mean concentration was 
calculated of 9.06 mg/1 with a standard deviation of 0.14 and 
98.60 ± 1.66 mg/1, respectively. The relative standard deviations 
were 1.46% and for the high concentration 1.68%, so again no 
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systematic changes occurred over the entire concentration range 
observed, with respect to the reproducibility of the method. 
Currently the method is in use for the measurement of the 
diflum'sal concentration in plasma of patients chronically 
medicated with the drug in the setting of a clinical trial. In 
connection with this trial a preliminary study of some 
pharmacokinetic characteristics of diflunisal in volunteers after 
ingestion of a 500-mg dose either as tablets or as capsules, has 
been established with this procedure. The results are shown in 
Fig. ?. Obviously diflunisal is well absorbed, has a small 
apparent volume of distribution (less than 10 1) and a plasma 
halflife time about 10 h at the dose level applied. The method 
reported here is very suitable for pharmacokinetic studies and 
drug level monitoring of diflunisal in man. 
100· 
5 0 0 mg dtflunisol In α human volanteer 
Δ · 2 tablets of 250 mg 
0 - 2 „ m capsules 
Fig. 2. Plasma curves obtained after oral administration of 500 
mg diflunisal to a female volunteer,21 years old, height 172 cm 
and weight 58.9 kg. Δ = 2 tablets of 250 mg; о = 2 tablets in 
capsules. 
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INTRODUCTION 
Naproxen i(+)-6-methoxy-a-methyl-2-naphtalene-acetic acid; 
Fig.1,1} is a nonsteroidal anti-infiammatory drug which is used 
extensively for the treatment of arthritic diseases (1). In the cour-
se od a study on the clinical efficacy of several MSAID compounds 
we are investigating also the pharmacokinetic profile of naproxen 
as related to its therapeutic effectiveness. For these studies we 
needed a rapid and accurate procedure for the quantitative 
analysis of naproxen in plasma and urine. Since it is known from 
literature data (2) that naproxen in man undergoes two major 
biotransformations, viz. demethylation to 6-0-des-methylnaproxen 
(II) and conjugation with glucuronic acid, the procedure should 
differentiate between these compounds. The analysis of naproxen 
in biological samples has been the subject of various reports. 
Gas-liquid chromatography has been used (3, 4, 5) but this 
requires a derivatization step for estrification of the carboxyl-
ic acid function of naproxen. We have experience with gas-liquid 
chromatography of naproxen after methylation with diazomethane. 
Although this procedure gives excellent results in general, it 
has a major drawback in the fact that the des-methyl-metabolite 
(II) yields the same methylated compound as naproxen itself. Of 
course it is possible to obtain a better specificity by using 
other derivatization techniques, e.g. butylation (3). An 
interesting and relatively sensitive analytical method for 
naproxen makes use of the strong fluorescence of naproxen (6,7 
8). Direct spectrophotofluorometry however requires rather 
extensive procedures for extraction and sample preparation and 
purification. And even then, application of direct fluorometry 
to samples of patients, receiving sometimes comedication with a 
number of other drugs, carries a large risk of interferences. 
Since we wanted to avoid complicated sample preparation and 
derivatization techniques we developed a specific high 
performance liquid chromatographic method for the determination 
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of naproxen and its des-methyl-metabolite in biological fluids. 
Although several methods have been described for the HPLC analysis 
of naproxen in biological samples (9, 10), in our hands the 
methods lack the sensitivity needed for thorough pharmacokinetic 
studies. In this paper we report the HPLC analysis of both 
naproxen and des-methyl with subsequent detection and 
quantification by spectrophotofluorometry. This method is 
compared with the standard U.V. detection and its advantages are 
discussed. 
ÇH3 
f ^ ^ V - CH-COOH 
С Н з О Л - Д ^ 
naproxen I 
СНз 
r J ^ T ^ i - CH-COOH 
C 2 H 5 O - I ^ ¿ 1 ^ 
ethyl-naproxen Ш 
СНэ 
г ^ Ч г ^ ^ і
-
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\ 
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Fig.l. Structural formulas of naproxen (I), б-0-des-methyl-
naproxen (II), ethoxy-naproxen (III) and diflunisal (IV). 
MATERIALS AND METHODS 
Materials 
Naproxen as well as 6-0-des-methyl-naproxen were kindly 
supplied by Syntex Research (Palo Alto, Calif., USA). Diflunisal 
(IV), used as an internal standard, was kindly supplied by 
Merck, Sharp and Dohme (Brussels, Belgium). The other internal 
standard, the ethoxy-analog of naproxen (III),was obtained from 
Syntex Research (Palo Alto, Calif., USA). The column packing 
material used was Lichrosorb RP 8 (5 pm) which was obtained 
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from E. Merck (Darmstadt, GFR). All other chemicals were of 
analytical grade and also obtained from Merck. 
Apparatus and chromatography 
A Hewlett-Packard 1081 В high performance liquid Chromatograph 
was used, equipped with an automatic sampling system and a HP 
fixed wave-length (254 nm) U.V. detector. The output of the 
detector was fed to the HP 3351 Lab Data System, which was 
operated in the internal standard mode. The fluorescence detector 
used was the Perkin Elmer model 3000 fluorescence spectrometer 
which was operated at an excitation wave-length of 235 nm (slit 
width 10 nm) and an emission wave-length of 350 nm (slit 5 nm). 
The column was stainless steel, 15 cm χ 4.6 mm I.D. and was 
packed with Lichrosorb RP 8 (5 μπι). The mobile phase was a 
mixture of methanol and citrate buffer (pH 6.5, 0.01 M). The 
methanol-buffer volume ratio was 50:50 for plasma and 40:60 for 
urine. The flow rate was fixed at 1.5 ml/min and the column 
temperature at 300C when U.V. detection was used. In case of 
fluorometric detection the flow rate was lower (1.0 ml/min) but 
the temperature higher (350C). A major factor in this respect is 
the large injection peak in case of U.V. detection, which is 
absent in fluorometric detection. These differences were 
desirable for obtaining optimal conditions in both cases. In the 
experiments with U.V. detection diflunisal was used as internal 
standard. The fluorescence detection necessitated the use of 
another standard, with fluorescence properties equal to those of 
naproxen; for that purpose the ethoxy-analog was used. 
Sample preparation 
Plasma (0,5 ml) was pipetted into a stoppered test tube, 
containing the internal standard, along with hydrochloric acid 
(0,7 ml, 1.5N). After homogenization the mixture was extracted 
with 5 ml of a mixture of diethyl-ether and n-hexane (1:1 volume 
ratio) by mechanical shaking for 30 minutes. After centrifugation 
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for 15 min at 1500 g, the organic layer was transferred into 
another tube and evaporated at 30 С under a gentle stream of dry 
filtered air. The residue was reconstitued in 1 ml of the mobile 
phase and aliquots of 10 μΐ were injected into the column. When 
fluorometric detection was applied the reconstituted residue of 
samples containing over 10 ug/ml was diluted 20-fold prior to the 
injection of again 10 μΐ. 
When urine samples (usually 0,25 ml) were analyzed the same 
procedure was foil owed,except for the acidification which was 
performed with acetic acid (4.2N) instead of hydrochloric acid. 
The reason for this modification was the fact that des-methyl-napro­
xen,which is present inmost urine samples but never in plasma 
samples in measurable amounts, appeared to be unstable during 
the sample preparation procedure when hydrochloric acid was used. 
For plasma samples we prefer acidification with hydrochloric acid 
because it results in a better precipitation of plasma proteins. 
Calibration and recovery 
Calibration was performed by adding known amounts of naproxen 
to blanc plasma or blanc urine samples and by handling these 
according to the procedure outlined above. Since urine samples 
usually contain both naproxen and its metabolite des-methyl-
naproxen also calibration for the latter had to be performed in 
case of urine samples. Calibration graphs were obtained by 
plotting the concentration of naproxen calculated by the data 
system against the concentration added. The data system was 
operated in the internal standard mode and calibrated with one 
of the known added concentrations, usually 50 yg/ml. For the 
calculations peak height ratios of naproxen to internal standard 
were used. The overall recovery of naproxen in the procedure was 
determined by comparing peak height ratios obtained after direct 
injection of standard solutions to peak height ratios of 
extracted naproxen solutions to standard solutions of the internal 
standard. 
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RESULTS AND DISCUSSION 
Under the conditions described no interference from endogenous 
compounds in plasma or urine is encountered (Fig. 2a). Table I 
lists the retention times of naproxen, its des-methyl-metabolite 
and some other anti-inflaimatory drugs'in the chromatographic 
system employed. It is obvious that also these compounds are not 
likely to cause difficulties in the analysis of naproxen. It may 
be important to notice already here that in plasma samples we 
never were able to detect any des-methyl-naproxen. This metabolite 
however is consistently found in urine samples. Probably the rate 
of excretion, augmented with the rate of further metabolism 
(conjugation to glucuronic acid) is so high that the metabolite 
is eliminated very shortly after it has been formed, so that no 
appreciable plasma levels are reached. The recovery of naproxen 
taken through the whole procedure was 95% on the average, without 
any systematic variations. The other chromatographic parameters 
are dependent upon the method of detection and therefore they are 
indicated separately in the following: 
Ultraviolet detection 
Calibration graphs were constructed for naproxen concentrations 
ranging from 1-100 yg/ml. A plot of naproxen concentrations as 
calculated by the data system (y) versus the concentration of 
naproxen added (x) yielded a perfectly straight line, fitting 
the equation: 
y = 0.949Χ + 1.511 „> 
(correlation coefficient = 0.9999 , η = 6). 
This equation results when calibration is performed with the 
50 pg/ml sample. Since the data system neglects the intercept of 
equation 1 it is obvious that optimal analytical results can only 
be obtained when the calibration point is as close as possible to 
the samples to be analysed. 
The overall precision of the method was measured on the basis 
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Table I 
Retention times of naproxen and some other anti-inflammatory 
drugs in the chromatographic system described in the text. 
salicylic acid 
б-0-des-methyl-naproxen 
oxyphenbutazon 
naproxen 
ethoxy-naproxen 
Phenylbutazon 
diflunisal 
mefenamic acid 
flufenamic acid 
RTa 
(min) 
1.65 
1.70 
2.55 
3.60 
5.20 
5.70 
6.25 
12.75 
17.60 
RTb 
(min 
2.30 
4.80 
7.00 
a flow 1.5 ml/min, column temperature 30 С 
b flow 1.0 ml/min, column temperature 35 С 
34 
of samples with 3 different concentrations. The results of table 
II clearly are illustrating the fact that accuracy is best for 
concentrations near to the point of calibration of the data 
system (50 ug/ml). 
The sensitivity of the procedure is comparable to that of 
common G.C. procedures: when using 0.5 ml samples concentrations 
of 1 yg/ml can be determined in principle, but for routinely useful 
application concentrations of a factor 2-5 higher are necessary. 
Fluorometric detection 
Under the circumstances of optimal fluorescence of naproxen 
the original internal standard diflunisal did not show any 
fluorescence at all. The fluorescence of diflunisal is optimal at 
an excitation wave-length of 235 nm and an emission wave-length of 
410 nm. The second standard, the ethoxy analog of naproxen, 
appeared to be suitable (fig. 2b). Calibration in this case was 
performed with the use of two different amounts of internal 
standard: for the naproxen range from 0.1-10 pg/ml sample the 
amount of standard was 1.25 ug and for the naproxen range from 
5-100 yg/ml sample an amount of 25 ug was employed. In both cases 
linear calibration graphs were obtained by plotting the amount of 
naproxen calculated (y) against the amount added (x): for the 
naproxen range 0.1-10 yg/ml sample (calibration 5yg/ml). 
y = 1.029Χ - 0.012 ,2> 
(correlation coefficient = 0.9993 , η = 5) 
and for the naproxen range 5-100 yg/ml sample (calibration 
50 yg/ml) 
y = І.ЮІЗх + 0.215 
(correlation coefficient = 0.9995 , η = 5) (3) 
As compared with equation 1 it is obvious that the value of the 
intercepts in equations 2 and 3 are substantially smaller. This 
indicates a higher sensitivity and better accuracy in the low 
concentration range. It is obvious that the slopes of equations 
2 and 3 are very similar. In fact a very satisfactory calibration 
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Table II 
Overall precision of the method with U.V. detection as 
i l l u s t r a ted by 10-fold analysis of three d i f fe rent 
concentrations of naproxen added to plasma samples. 
added 
(yg/ml) 
5.08 
50.80 
101.60 
found 
(pg/mi) 
5.85 
50.49 
100.50 
standard 
deviation 
0.140 (2.40%) 
0.361 (0.71%) 
3.14 (3.13%) 
Table III 
Overall precision of the method with fluorometric 
detection of naproxen (cf. table II). 
added 
(ug/ml) 
1.536 
10.24 
51.20 
102.40 
found 
(yg/ml) 
1.504 
10.14 
51.18 
103.87 
standard 
deviation 
0.024 (1.6%) 
0.14 (1.4%) 
0.62 (1.2%) 
1.24 (1.2%) 
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(4) 
graph for the whole concentration range can be obtained by 
combining all data in one equation: 
y = 1.1017X + 0.537 
(correlation coefficient = 0.9997 , η = 10) 
Although this equation confirms the overall linearity it is clear 
that accurate measurements in the lower concentration range can 
only be performed by using equation 2 based on addition of the 
lowest amount of internal standard. 
The precision of the fluorometric method again was measured by 
repeated analysis of samples with different concentrations and 
appears to be at least as satisfactory as that of the U.V. 
procedure as can be seen in table III. The sensitivity of this 
procedure is definitely higher than that of the U.V. procedure. 
When using 0,5 ml samples concentrations of 0.1 yg/ml can be 
determined. 
0 5 10 15 о 5 
retention time ( m m ) 
Fig. 2a. HPLC chromatogram of naproxen (A) and d i f l u n i s a l (B) 
af ter extraction from plasma, using u l t r a v i o l e t detection. 
Fig. 2b. HPLC chromatogram of 6-0-des-methyl-naproxen (A), 
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naproxen (В), ethoxy-naproxen (С) after extraction from urine, 
using fluorescence detection. 
CONCLUSION 
The procedures described combine ease of handling with 
accurate and sensitive analytical results. Furthermore they are 
suitable for routine measurements and can easily be adapted to 
automatic analysis. The procedure with U.V. detection in our 
experience is very suitable for the routine measurement of 
naproxen plasma levels of patients during chronic medication. 
Results of such measurements combined with their clinical and 
pharmacological significance will be reported elsewhere. When, 
however, studies of the detailed pharmacokinetics of naproxen 
after single dose are concerned or in other cases where the 
accurate measurement of low concentrations of naproxen is 
required, or when only very small samples are available the 
fluorometric detection method becomes necessary when high 
performance liquid chromatography is the analytical method of 
choice. As an example of such a situation (fig. 3) shows the 
plasma curve of naproxen after oral administration of a 250 mg 
dose to a human volunteer. The plasma curve appears to obey two-
compartment kinetics, although in previous studies a kinetic 
analysis according to a single compartment model is proposed 
(11). Details of this pharmacokinetic behaviour will be 
published elsewhere. Finally table IV shows a set of experimental 
data, viz. plasma concentrations of naproxen in a volunteer, 
that have been calculated by high pressure liquid chromatography 
with U.V. as well as fluorometric detection. These data indicate 
that both methods are equally reliable in the concentration range 
in which the U.V. procedure can be adequately applied. 
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Fig. 3. Computer fitting of a plasma curve of naproxen 
sodium, using a two-compartment model. The concentrations 
were assessed with the spectrofluorometric detection method. 
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Table IV 
Comparative analysis of 9 plasma samples of a human 
volunteer after an oral dose of 250 mg of naproxen, 
by U.V. detection and fluorometric detection. 
time after 
administration 
(hr) 
0.5 
1.0 
2.0 
3.1 
4.2 
6.3 
8.0 
12.0 
24.3 
U.V. 
(yg/mi) 
65.62 
60.45 
49.97 
42.89 
37.04 
30.74 
28.58 
19.31 
12.29 
fluorometry 
(yg/ml) 
67.16 
60.96 
50.59 
44.28 
38.47 
31.97 
28.78 
19.60 
12.22 
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SUMMARY 
A HPLC method for the quantitative analysis of naproxen and 
its major metabolite des-methyl-naproxen in biological fluid 
samples is described. 
Two methods of detection are compared: U.V. spectrophotometry 
and spectrophotofluorometry. In both procedures an internal 
standard is used: diflunisal in the U.V. procedure and the 
ethoxy-analog of naproxen during fluorometry. The sensitivity 
of the fluorometric detection is higher than that of the U.V. 
detection; the limit being respectively 0,1 yg and 2,0 pg per 
milliliter sample. Fluorescence detection procedure can also be 
applied to very small samples (0,05 ml) in the therapeutic 
concentration range. Both procedures have been applied to 
clinical and laboratory studies in which they appear to be very 
satisfactory because of their ease of handling and their 
suitability for routinely performed analysis. 
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INTRODUCTION 
The primary symptoms for which patients suffering from rheumatoid 
arthritis seek medical attention,are pain and stiffness. Until new 
classes of antirheumatic drugs emerge, anti-inflammatory analgesics 
remain the drugs of choice for these complaints. Long-term treatment 
with these drugs is frequently complicated by side effects, which 
cause numerous patients to discontinue their treatment with esta-
blished drugs like salicylates, indomethacin and phenylbutazone. In 
England and especially in the USA»salicylates are still recommended as 
drugs of choice (1,2). This preference is mainly based on economical 
and historical grounds (long established clinical practice), but dis-
regards the high incidence of serious gastro-intestinal complications 
(3)and CNS side effects. Pharmacological and clinical research has 
focused on new classes of non-steroid anti-inflammatory drugs (NSAID) 
equalling the older drugs in antiphlogistic and analgesic properties, 
but with a better tolerance. In western Europe patients treated with 
these drugs probably already outnumber those treated with salicylates. 
Naproxen, a drug that belongs to the group of propionic acid 
derivatives, shows a better balance between therapeutic and side 
effects (4). Its sodium salt has a shorter reabsorption time (5) 
and, on theoretical grounds, it should also have fewer gastric 
side effects because it has a lower capacity to penetrate into the 
stomach mucosa than the acid. Diflunisal, another NSAID, has more 
marked anti-inflannatory and analgesic effects than its parent drug 
salicylic acid, and in addition seems to have fewer side effects 
(6). This drug may therefore afford interesting possibilities in 
the treatment of rheumatoid arthritis. The present clinical trial 
was designed to study and compare the antirheumatic efficacy and 
safety of naproxen and diflunisal. 
The optimal duration of clinical trials with NSAID in rheumatoid 
arthritis is still controversial (7, 8). Our choice for a long-
term clinical trial is based on two considerations. Firstly, 
although it is possible to test the analgesic and antiphlogistic 
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effect of a drug during a short period (2 to 6 weeks), it is diffi­
cult to extrapolate short-term results to long-term treatment of a 
disease with such a capricious course. Secondly, complications of 
therapy with NSAID are not restricted to the initial phase of thera­
py. At the time the trial was started, no reports existed on the 
use of diflunisal in rheumatoid arthritis. The dose we chose (250 
mg a.m., 500 mg p.m. daily) was larger than that advised in osteo­
arthritis (250 mg b.i.d.) because RA requires higher drug concen­
trations (the antiphlogistic effect emerges at concentrations 
higher than those needed for analgesia (9), just as is the case 
with salicylic acid). 
MATERIALS AND METHODS 
Materials 
Placebo capsules matching the representation of the active drugs 
were used in the placebo pulse phase. Naproxen-sodium (NS) 275 mg 
capsules (250 mg naproxen) were provided by Sarva-Syntex B.V., The 
D 
Nether-lands. Diflunisal (D) 250 mg tablets (Dolocid ) were commer­
cially obtained from MSD Ltd., England. The tablets were used in an 
encapsulated form matching the representation of NS. There were no 
pharmacokinetic differences as to onset of reabsorption, С max, area 
under the curve and Ц between the tablets and their encapsulated 
form. Paracetamol 500 mg tablets (Onderlinge Pharmaceutische Groot­
handel В.V., The Netherlands) were used as an additional analgesic 
drug. Grip strength was measured with a sphygmomanometer ( La 
Filoiatrica, Italy) with a detection range from 3 to 300 mm Hg. 
Methods 
Trial design 
Patients with a classical or definite rheumatoid arthritis, 
according to the revised ARA criteria (10), participated in the 
study and informed consent was obtained from all. The trial was 
double blind and the patients entered the trial during a period of 
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9 months. During a period of at least 48 hours and maximally one 
week, all NSAID therapy was discontinued and the patients received 
placebo. During this period they had to show deteriation of symptoms 
by at least 10 points on the scale of the Ritchie index, to 
establish the need for analgesic/antiphlogistic therapy. No other 
antirheumatic drug therapy was allowed than hydroKychloroquine (5 
patients) and aurothioglucose (12 patients) with a dose regime 
stable over a period of at least 3 and б months, respectively. Both 
drugs were equally distributed among the treatment groups. Physio­
therapy remained unchanged during the trial period, but no new 
treatment was started. 
evening dose 5 5 0 mg naproxen - sodium or 500 mg dillunis«! 
morning dose 2 7 5 m g naproxen- soaium or 2 5 0 m g dillumsal 
1 0 1 2 4 6 10 14 18 2 І 
dates OF visit time (weeks) 
Fig. 1. Schedule of dates of visits, wash-out period and 
medication throughout the trial. 
All patients were seen at each visit (week -1, 0, 1, 2, 4, 6, 
10, 14, 18, 24) between 1 and 4 p.m. by the same observer (JvL) 
(fig.l). The following clinical assessments were made: Ritchie 
index (11), pain during day and night, morning stiffness, duration 
and severity, overall evaluation of therapy by patient and doctor 
and measurement of grip strength (mean of 3 assessments). The 
Ritchie index of joint pain during external pressure was determined 
as described by Katz (12). The scales used for assessment of pain 
and stiffness were derived form the ARA functional classification 
(13, 14). Morning stiffness duration was defined as the time from 
arising until the moment of easing, maximally 4 hours. The sub-
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jective scores (patient's and doctor's evaluation) were graded: 
1 = excellent to 4 = doubtful or no therapeutic result, and pain 
and stiffness in the same way (14). Prior to the trial and after 
week 24 a full physical examination and an ECG were made, showing 
no changes over the time. At the end of the placebo phase and after 
week 14 and 24 the following laboratory assessments were made: 
haemoglobin, haematocrit, ESR, leucocyte count and differential 
count, platelets, serum alkaline phosphatase, bilirubin, ASAT 
(GOT), creatinine, urea and uric acid. At the same visit the urine 
was examined microscopically and checked for glucose and albumen. 
A test for occult blood (positive over 2 ml a day) in the faeces 
was made at the end of the placebo period and in the trial, during 
a haemoglobin-free diet. With the exception of the laboratory data 
mentioned in the tables, no statistically significant changes 
occurred. The plasma drug concentrations were assessed by a HPLC 
method (15, 16). 
Statistical analysis 
Student's t-test was used for assessment of statistical signi­
ficance of the data. Ρ values of < 0.05 were considered to be 
statistically significant. Since there were some imbalances between 
the two groups regarding the starting values of some parameters 
(Ritchie index, pain at night and the logarithmic values of morning 
stiffness and grip strength), the t-tests were employed with co-
variance adjustments for the initial difference. The overall 
comparison was made by multivariate analysis with Hotel ling's Τ 
test. All parameters were regarded as having the same importance. 
The logarithmic values of the differences in grip strength + 1 
were used in Hotel ling's Τ test. All values are expressed as mean 
value i standard deviation. 
RESULTS 
Thirty-nine patients entered the study. Twenty-two allocated 
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to NS, 17 to D. The mean duration of disease in years was 5.0 + 1.0 in the 
NS group and 6.9 + 1.6 in the D group. The anatomical stages (13) were 2.2 
+ 0.2 in the NS group and 2.1 + 0.2 in the D group. The functional classi­
fication (13) was 1.9 + 0.1 in the NS group and 1.5 + 0.1 in the D group. 
Pre-treatment values of the Ritchie index, pain, morning stiffness, ESR and 
haemoglobin of the individual patients are shown in figure 2 a, b, c, d, e, 
f. There were 3 drop-outs (cases 1, 2 and 3) in the D group due to insuffi­
cient control of pain and stiffness. In the NS group one female patient 
(case 4) dropped out due to insufficient control of pain, and she complained 
also of muscular cramps in both legs. Another patient (case 5) was excluded 
form the trial because of deep venous thrombosis of the calf, necessitating 
anticoagulant therapy. 
Fig. 2. Values in the individual patients at day 0 of the following 
parameters: pain (a), morning stiffness duration (b), morning stiffness 
severity (c), Ritchie index (d), ESR (e) and haemoglobin (f). Patients who 
dropped out of the study are indicated by open squares and individually 
numbered. 
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Α Π cl i m ca I parameters showed statistically significant improve­
ment as compared with the placebo period after week 2.Thi3 effect 
persisted throughout the trial for both drugs (table I). The im­
provement in grip strength was less significant (0.01 < ρ < 0.05) as 
compared with the other parameters. Temporarily there were some statis­
tically significant differences in some parameters between both groups. 
They are indicated in table I. Table II showes the laboratory assess­
ments. At week 24 the ESR in the D group showed a statistically sig­
nificant fall from baseline values. At that time the difference be­
tween NS and D was also statistically significant. The haemoglobin 
concentration in the NS group at week 24 was significantly lower than 
baseline values and values in the D group. The uric acid concentra­
tions in the D group fell by 0.08 mmol/l + 0.02 as compared with 
baseline values. During the placebo and active drug phase, occult 
blood tests were positive in 29% and 35% in the D group and 14% and 
32% in the NS group, respectively. The need for additional analgesic 
therapy was not significantly different between the two groups, but 
it increased slightly from 0.6 tablet per week in both groups at 
week 6 to 1.9 tablets in the D group and 2.2 tablets in the NS group 
at week 24 (tablets per patient per week). Patients compliance as 
measured by returned tablet count (less than 5%) was good. Table III 
lists the complaints reported during the trial. 
The ρ values of the differences of the overall assessments of the 
clinical parameters and their changes during treatment by means of 
Hotelling's Τ test are given in table IV. 
Table IV Ρ values of the differences of t i e overall assessments* of the clinical paraireters 
conparing the NS- and the С treated g-cjp 
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The majority of 376 clinical parameters measured at subsequent 
visits were not significantly correlated. The Ritchie index was sig­
nificantly correlated with other clinical parameters 22 out of 58 
times in the NS group and 16 out of 52 times in the D group. Changes 
in grip strength (left compared with right) were significantly cor­
related 5 out of 8 times in the NS group and 6 out of 8 times in the 
D group. The severity of morning stiffness and its duration were 
significantly correlated 5 out of 8 times in the NS group and 4 out 
of 8 times in the D group. The changes of all clinical parameters, 
except grip strength, in the individual patients correlated signifi­
cantly with their initial values (mean r = 0.7 + 0.1; ρ < 0.01). 
We also calculated the correlation, for the whole groups and for both 
sexes separately, between the plasma drug levels at each visit and 
the clinical parameters and lab values as well as their respective 
changes, resulting in 792 calculations. Of these 792, only 21 corre­
lations were statistically significant; 18 were distributed in no 
particular pattern. Of interest was a cluster of three correlations 
between the Ritchie index values and diflunisal plasma concentra­
tions, namely at week 1, 14 and 28 (r = -0.5;p < 0.05). 
DISCUSSION 
Our data indicate that both drugs used in this study caused 
statistically significant improvement of all clinical parameters as 
compared with the placebo period. This effect was already apparent 
2 weeks after starting the effective drugs and persisted throughout 
this long-term clinical trial. Maximal improvement occurred at week 4 
to 6;thereafter there was a tendency to decline, as manifested by an 
increased need for additional analgesics and a slight over-intake 
of the effective drug at week 24 (data not shown). There were no 
significant differences in clinical effectiveness between the two 
drugs, except for a period between week 4 and 10, when some para­
meters were significantly better in the D group. Possibly the tempo-
rariness of these differences is due to development of tolerance to 
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the central component of the analgesic effect, which has been shown 
for salicylic acid (17). After the abovementioned period, any dif­
ference in clinical efficacy between NS and D was highly unlikely 
because of the very high ρ values, especially at week 24 (table III). 
Five patients dropped out during this clinical trial, but none 
of them because of side effects. Four patients (3 in the D and 1 in 
the NS group) dropped out in the early phase of the trial in view 
of insufficient control of clinical signs and symptoms. So far as D 
is concerned, this may be related to the rather small dose of this 
drug used in this trial {larger doses of D have been used for RA 
patients in 2 recent reports (18, 19)}. It is to be noted that all 4 
drop-outs showed high initial disease activity. This suggests that 
for this type of clinical trial it may be useful to define not only 
minimal disease activity {as has been advocated (20)}, but also 
maximal initial disease activity. Patient compliance, as judged from 
returned tablet counts, appeared to be satisfactory and relatively 
stable throughout the trial period. Starting from the statement that 
patient compliance is a measure of the patient's appreciation of the 
treatment (21), it can be said that both drugs tested are effective 
NSAID with good tolerance. Since a distinct correlation was found 
between changes in clinical parameters and their initial values, it 
seems justified to start antirheumatic therapy with these drugs even 
in the presence of severe complaints related to disease activity. 
In the D, but not in the NS treated group of patients, there 
appeared to be a relationship between changes in laboratory and 
clinical parameters, resulting in the seemingly paradoxical situation 
that after week 14 there was no difference in clinical efficacy 
between NS and D, whereas laboratory values differed significantly. 
Another difference between NS and D is related to the significance 
of plasma drug concentrations. With the possible exception of sali­
cylic acid (22), plasma drug concentrations have never been demon­
strated to be a useful correlate for the clinical efficacy of NSAID. 
Since we found a correlation between Ritchie index and plasma 
concentrations of D, there is probably a relationship between plasma 
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drug levels and clinical efficacy for this drug. This does not mean, 
however, that our data justify the use of plasma drug concentrations 
as a guideline for adjustment of therapy. 
Patients with rheumatoid arthritis show great intra- and inter-
individual variations in disease activity. In clinical trials this 
easily leads to inhomogeneity of patient groups and difficulties in 
statistical analysis of the data obtained. The latter especially 
applies to long-term trials and still is a matter of concern (23, 
24). We have chosen to obviate the problem of the initial inhomo­
geneity of group by applying co-variance correction. The problem of 
the comparison of the overall assessments has been dealt with by 
multivariate analysis as effected by Hotelling's Τ test. Another 
possibility leading to the same result is stratified randomization 
after, for instance, half the number of patients have entered the 
trial. Since, in our study, only a small number of significant 
correlations existed between the sequential values of the single 
parameters, this indicates that they behaved more or less indepen­
dently, allowing the application of multivariate analysis. 
Our results suggest that data obtained in short-term trials 
can not simply be extrapolated to long-term use of the drugs. Our 
data show that several clinical effects, including effects on 
morning stiffness and pain during the night, may be temporary, re­
quiring and justifying long-term studies with NSAID (in our opinion 
during at least 24 weeks). Side effects were scattered over the 
whole trial period and, in most instances, not persistent. Only 
complaints noted more than once should probably be regarded as drug-
induced, but this approach is difficult in short-term trials. Side 
effects were rather mild and easy to handle. Complaints of tinnitus 
and vertigo in the D-treated group occurred only at plasma drug 
levels over 80 mg/1, and even then only occasionally (fig. 3). 
Grip strength, as indicated by other investigators (25), proved 
to be a parameter of modest value due to its low reproducibility and 
great individual variability. There was no demonstrable correlation 
between initial values and changes during drug treatment regarding 
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this parameter. A major reason for the unreliability of grip strength 
as a disease activity parameter seems to be related to the fact that 
irreversible lesions like muscle atrophy and joint destruction and 
deformity partly determine its measurement. The significance of 
another disease activity parameter, i.e. morning stiffness, has 
recently been questioned (26). It has been stated that severe pain 
can be reported as stiffness by the patient. If.then, disease 
activity decreases and stiffness lessens, pain relief is relatively 
small because pain scores have previously been flatteringly low. Our 
data support this view, since scores for stiffness decreased by 65%, 
whereas daytime pain scores decreased by only 36%. 
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Fig. 3. Plasma diflunisal concentrations in patients occasionally 
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advantages during a short period, we tend to prefer naproxen in view 
of its safer pharmacokinetic profile as compared with the capacity 
limited eliminations of diflunisal which entails a risk of accumula-
tion. 
SUMMARY 
A double blind long-term clinical trial was designed to study 
and compare the antirheumatic efficacy and safety of naproxen sodium 
(NS) and diflunisal (D). Twenty-two patients were allocated to the 
NS- and 17 to the D-group receiving 825 mg NS (500 mg naproxen) and 
750 mg D daily, respectively. Three patients in the D- and 2 patients 
in the NS-group dropped out, none of them because of side effects, 
which were usually mild and not persistent. All clinical parameters 
showed statistically significant improvement as compared with the 
placebo period after week 2, an effect persisting throughout the 
trial for both drugs. The changes of all clinical parameters, except 
grip strength, in the individual patients correlated significantly 
with their initial values. Maximal improvement occurred at week 4 
to 10; thereafter there was a tendency to decline, as manifested by 
an increased need for additional analgesic (paracetamol) and a slight 
over-intake of the effective drugs at week 24. Using multivariate 
analysis there were no significant differences in overall clinical 
effectiveness between the two drugs, except at week 6 and 10 for the 
actual values and at week 6 for the change from baseline, when 
significant differences existed in favour of the D group. In the D, 
but not in the NS treated group,improvement in ESR values paralleled 
that of the clinical parameters. Also in the D group, we found a 
correlation between Ritchie index and plasma concentrations of D. 
Our data indicate that NS and D are equally safe and effective as 
NSAID in the long-term treatment of patients with rheumatoid 
arthritis. 
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CHAPTER V 
Persistent hypouricemic effect of longterm diflunisal 
administration 
J.W.A. van Loenhout, L.B.A. van de Putte, F.W.J. Gribnau, 
C.A.M. van Ginneken 
This chapter was published in "Journal of Rheumatology", 
8 (1981), in press. 
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INTRODUCTION 
Salicylic acid influences uric acid handling by the human 
kidney. While small doses (0.5 - 2.0 g daily) cause uric acid 
retention, larger doses have a uricosuric and hypouricemic effect 
(1). Large salicylic acid doses frequently cause intolerable 
gastrointestinal and central nervous system (CNS) side effects. 
They are, therefore, unacceptable to treat gout (2). 
Diflunisal, a new salicylic acid derivative with less toxic side 
effects (3) than salicylic acid,has been reported to have uricosuric 
and hypouricemic properties (4) in relatively small doses (0,5-l,0g) 
daily) that have analgesic and antiphlogistic effects (5). The 
hypouricemic effect (4) was studied in young healthy volunteers 
during short-term administration of the drug. The lowering of the 
mean plasma uric acid concentration from ί 0.26 mmol/1 to 0.20 
mmol/1 was reported in osteoarthritis during a clinical trial of 
500 mg diflunisal daily for 2 weeks (3). In a trial of 48 weeks 
comparing the effect of diflunisal versus naproxen sodium on 
rheumatoid arthritis (RA) (manuscript in preparation) we studied 
the hypouricemic effect of chronic administration of diflunisal. 
MATERIALS AND METHODS 
Fourty-one patients with classical or definite RA according to 
the ARA criteria participated in our trial that was double blind 
for 24 weeks. Thereafter 10 patients continued diflunisal for 
another 24 weeks. Relevant data are given in table I. All other 
nonsteroidal antiinflammatory drugs (NSAIDs) were discontinued 
1 week before the start of the trial. No other medication was 
used except hydroxychloroquine (3 patients), aurothioglucose 
(6 patients) and paracetamol (6 patients) for additional analgesia 
all drugs being equally distributed among both groups. Disease 
activity measures (morning stiffness, pain, Ritchie index, grip 
strength, erythrocyte sedimentation rate (ESR), hemoglobin) were 
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not statistically different between the group at weeks 0, 14, 24 
and 48. The dosages of the drugs were: diflum'sal (DolobidR, 
Merck, Sharp and Dohme Ltd., England, 250 mg tablets, commercially 
obtained), 750 mg daily and naproxen sodium (275 mg capsules 
provided by Sarva-Syntex BV, The Netherlands) 825 mg daily. 
Table I. Data on trial population and clinical assessments 
Diflunisal Naproxen sodium 
54.4 + 10.4 
18 
7 : 11 
37.2 + 5.5 
24.3 І 2.6 
8.7 Í 0.2 
24.0 ± 4.0 
12.2 ± 1.8 
8.8 t 0.2 
age (yr, mean + SD) 
number of patients 
female/male 
ESR (rnn/h) 
Ritchie index 
hemoglobin (mmol/1) 
ESR (mm/h) 
Ritchie index 
hemoglobin (mmol/1) 
53.3 + 9.8 
23 
13 : 10 
41.3 + 50 
22.4 t 2.4 
8.7 + 0.2 
40.1 + 6.3 
11.5 ± 1.9 
8.1 Í 0.2 
The diflunisal and naproxen concentrations were assessed by 
a high-performance liquid chromatographic method (6). The serum 
uric acid (SUA) concentrations were determined by the uricase 
method (7). Statistical analysis of the correlation coefficient 
was performed with Student's t test, ρ values of less than 0.05 
being accepted as statistically significant. Data throughout the 
text are expressed as mean value plus or minus standard error 
of the mean (mean ± SEM). 
RESULTS 
In the diflunisal-treated group there was a significant 
(p < 0.001) fall in mean SUA concentration from 0.28 mmol at week 
0 to 0.22 mmol/1 at week 14 and 0.20 mmol/1 at week 24. In the 10 
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patients followed until week 48, the mean SUA concentration 
remained at 0.20 ± 0.02 mmol/1. There was a slight but not 
significant rise in the mean serum creatinine concentration in 
the diflum'sal-treated group, the greatest rise being from 58 to 
86 ymol/l. The naproxen-treated group showed no significant 
changes in SUA and creatinine concentrations throughout the trial 
(Table II). There was a significant correlation (p < 0.01) 
between the changes in SUA and the diflunisal concentration at 
week 14 (Fig. la). A difference was observed in the mean change 
(Δ) of SUA concentrations between males and females, 0.05 t 0.02 
and 0.09 ± 0,02 mmol, respectively; the difference did not reach 
statistical significance. 
plasma diflunisal concentrations ( mg /1 ) 
4 0 80 120 160 200 240 4 0 8 0 120 160 200 240 
I I I I I I I I I I . I I I I I ι ι I I 1 1 1 1 L 
' 0 0 4 
5 ooo 
π - 0 0 4 
Ϊ 
X - 0 0 8 -
υ 
1-012 
Sc 
л 
Ό - 0 . 1 6 
а 
С - 0 2 0 -
< 
х=males 
• = females 
' t o t a l group 
r = 0 5 7 
p < 0 0 1 
w e e k M 1 3 ' 
• 0.04 
0 0 0 
- 0 0 4 
- 0 0 8 
- 0 12 
- 0 1 6 
- 0 . 2 0 
-
• X 
X 
X 
• 
X · 
X · 
X X X 
X 
• 
• 
• 
x=maies 
• = females 
males ' 
г = 0 5 8 
p< 0 05 J 
w e e k 2 4 t b ) 
Fig. 1. Correlations between plasma diflunisal concentrations and 
changes in serum uric acid concentration. 
At week 24 there was a significant correlation between the 
fall in SUA concentration and the diflunisal concentration, 
r = 0.576 (p < 0.05) in males. Throughout the trial the mean 
diflunisal concentrations were higher in the female group; this 
became significant at week 24 (p < 0.05), the diflunisal 
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concentration being 95 + 11 mg/1 in the female group and 66.0 + 7 
mg/1 in the male group (Fig. lb). After week 14, there was no increase 
in SUA concentrations even at low diflunisal concentrations. The 
intraindividual fall of SUA concentrations was maintained throughout 
the period of observation. 
Table II. The mean ± SEM for serum uric acid and creatinine 
concentrations. The diflunisal and naproxen concentrations 
are plasma measurements. 
Table I I 
DirLJMSAL NAPROXEN S00IJH 
Serum concentration jrlc acid creatinine diflunisal uric acid creatinine паргожеп 
(dirol/l) (.mol/l) i^g/l) (Trol/l) (jmol) (mg/l) 
week 0 3 2Θ ! С 02 7E S î 4 1 Ζ 2 0 29 ί 0 02 78 6 ΐ 3 D 0 0 
week ¡4 0 22 ! 0 02 82 9 І 5 1 65 I ! 7 7 0 29 î 0 02 77 2 ! 2 6 47 « ! 2 β 
week 24 0 20 : 0 0? 0. S ! S 0 77 S î S 8 0 30 î 0 02 76 4 '. 2 6 48 6 i 3 О 
DISCUSSION 
The mechanism of the renal handling of uric acid is still 
poorly understood and controversial. Recently Fai nel li and 
Weiner (8) discussed the model of an active transport mechanism, 
bi-directional, with very high fluxes, limited to the proximal 
tubule. In this model low concentrations of salicylic acid cause in­
hibition of uric acid secretion by the tubule cell in competition 
for the transport mechanism. With high salicylic acid serum 
concentrations the glomerular filtration of salicylic acid 
increases and this leads to high concentrations in the proximal 
tubule. In addition, this causes inhibition of reabsorption of 
uric acid. A net uricosuric effect may result, depending on the 
balance of the 2 mechanisms. Diflunisal is highly protein-bound 
(> 96%); free plasma concentrations are low so that, even at high 
plasma concentrations, the concentration of diflunisal in the 
glomerular ultrafiltrate is still low as compared with salicylic 
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acid, which has a protein binding capacity of about 65% (9, 10). 
The uricosuric effect of diflunisal at low free drug 
concentrations could be explained by very high affinity of 
diflunisal to the reabsorptive system of uric acid.In accordance 
with the positive correlation found between the diflunisal 
concentrations and the fall of the SUA concentrations, the 
statistically significant higher diflunisal concentrations in 
women are probably responsible for the greater fall in SUA 
concentrations within this subgroup. The difference in SUA levels 
between the diflunisal- and the naproxen-treated groups cannot 
be explained by a different rate of uric acid synthesis, because 
the drug did not differ significantly in antirheumatic efficacy. 
The rise in serum creatinine concentrations during treatment 
with diflunisal is probably similar to the rise reported during 
treatment with other NSAIDs which cause inhibition of 
prostaglandin synthesis (11) and therefore lower the renal plasma 
flow. We did not record a rise of the mean serum creatinine 
concentration in the naproxen-treated group. There could be 2 
explanations. The first, that it did not exist. The second and 
more likely one, since increased serum creatinine concentrations 
have been reported with naproxen (11), that it had already 
disappeared. This rise is usually reversible and diminishes with 
continued treatment. Microscopic examination of the urine 
revealed no uric acid crystals nor tubular epitheal cells in any 
patient during the period of observation. 
Diflunisal may be useful for treating oout, because it 
combines hypouricemic, analgesic and antiphlogistic properties at 
a dose level with few side effects. The drug's antiphlogistic 
property is an extra advantage because institution of 
hypouricemic treatment is often complicated by gouty attacks (12). 
Compared to the side effects of chrome treatment with allopurinol 
and/or colchicine, the side effects of small doses of diflunisal 
may be less. The drug was very well tolerated by our patients 
without drop-outs from side effects. We found no reports on its 
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use in gout. We have recently started a study of tne eff icacy of 
d i f l u m s a l treatment in patients with gouty a r t h r i t i s . The 
preliminary results in 4 patients suggest d i f l u m s a l is ef fect ive 
as a uricosuric agent in gouty patients with hyperuricemia, 
After 14 days of treatment with 1,000 mg dai ly the mean SUA 
concentration f e l l from 0.57 ± 10 mmol/l to 0.42 ± 0.11 mmol/1 
(mean + standard deviat ion). 
SUMMARY 
D i f l u m s a l , a s a l i c y l i c acid der ivat ive, caused a s ign i f icant 
f a l l in serum ur ic acid concentration from 0.29 + 0.02 to 0.20 + 
0.02 mmol/1 (mean + SEM) during chrome administration of 750 mg 
dai ly in 18 patients with rheumatoid a r t h r i t i s . There was a s i g n i f i ­
cant correlat ion between plasma d i f l u m s a l concentrations and f a l l 
of serum ur ic acid concentrations (p < 0.01) at week 14. Di f lumsal 
concentrations were s t a t i s t i c a l l y higher in females (p < 0.05) at 
week 24. 
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INTRODUCTION 
Amoxycillin, a widely used antimicrobial agent, is subjected to active 
transport mechanisms in the human kidney like other penicillins. This is 
evidenced by the observation that the renal elimination of amoxycillin can 
be inhibited by probenecid (1). The organic anion transport mechanism of 
the human kidney can also be influenced by diflunisal, as can be derived 
from the pronounced uricosuric effect of diflunisal (2, 3). Diflunisal 
is eliminated largely via capacity limited metabolic pathways in man, as 
can be concluded from the more than proportional increase of steady-state 
levels with higher doses (4). The drug being a non-steroidal anti-inflam-
matory is used in chronic treatment of patients with rheumatic diseases. 
During such medication the need for antimicrobial therapy might arise. The 
combination of diflunisal's capacity limited elimination (which implies an 
increased risk of accumulation and intoxication) and its ability to inter-
fere with the tubular secretion mechanisms, prompted us to investigate the 
possible pharmacokinetic interaction between diflunisal and amoxycillin 
in man. 
METHODS 
Materials 
D 
Commercially obtained capsules containing 375 mg amoxycillin (Clamoxyl , 
Beecham, The Hague, The Netherlands) and tablets of 250 mg diflunisal (Do-
D 
locid , M.S.D., Haarlem, The Netherlands), were used. Analytical grade 
reference substances were generously provided by the respective companies. 
ß-Glneuroni dase (type VII purified from E coli) was obtained from Sigma 
(St. Louis, Mo, USA). All other reagents were of analytical grade and ob-
tained from Merck (Darmstadt, GFR). 
Study design 
Six young healthy volunteers, 4 males and 2 females, participated in this 
study. Their age was 20.7 t 0.8 years, height 178 ± 6 cm, and weight 68 i 
4 kg (means t SD). No other drugs were used during a period of at least 1 
month prior to- and during the study. A full physical and laboratory exa-
mination as a check up for good health was made. The lab investigation com-
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prised: complete urinalysis, ESR, haemoglobin, serum creatinine, uric acid, 
bilirubin, alkaline phosphatase, ASAT and ALAT, and chemicaly determined 
albumin. All parameters were within the normal range. 
The study was designed in such a way, that the volunteers received 
repeated doses of 500 mg of diflunisal b.i.d. for 8-12 days. With this 
regimen steady-state plasma diflunisal concentrations were reached after 5 
days. Diflunisal levels were measured at day б and 8. Amoxycillin plasma 
levels were assessed after a single dose of 750 mg at day 8 and 3 weeks 
after discontinuation of diflunisal medication. In 4 volunteers plasma 
diflunisal and amoxycillin were also determined at day 12, after 4 days of 
coadministration of diflunisal 500 mg b.i.d. and amoxycillin 750 mg b.i.d.. 
Fig. 1 illustrates these experimental designs. 
Study d e s i g n amoxyci l l in -diflunisal interaction 
750nig 
diflunisal SOOmgbid ^  
(6 volunteers) [ j ι 
атохуаПтЁ j 
750mg Ь ι d [ i 
(4 volunteers! S 
-, гМ-
750mg 
M sompling 
1 2 3 4 5 6 7 β 9 10 11 12 33 time Idoys) 
Sampling 
At the days of sampling the volunteers had been fasting over night and 
remained fasting for an additional period of 2 hours after the intake of 
the drug(s) with 500 ml water. Blood samples were collected at 0, 15, 30, 
45, 60 minutes and 1.5, 2, 4, 8 and 12 hours after ingestion of the drugs. 
Urine samples were collected over 12 hours for the determination of diflu­
nisal and its glucuronides. The blood samples were collected in heparinized 
tubes and immediately centrifuged at 2000 g during 10 minutes. All samples 
were stored at -800C. 
Analytical procedures 
Amoxycillin concentrations were assessed with a microbiological method 
(5). Diflunisal concentrations up to 300 mg/ml did not have any influence 
on the amoxycillin assay. Diflunisal concentrations were determined with 
a HPLC method (6). Of every aliquot of urine 1 ml was used for the diflu-
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nisal determination and another ml for the measurement of diflunisal and 
its glucuronides together. For the latter measurement the sample was 
adjusted to pH 6.8, after which a 0.075 M phosphate buffer pH 6.8 con-
taining 500 units of ß-glucuronidase was added. The mixture was then in-
cubated for 21 hours at 370C and subsequently processed (6). 
Pharmacokinetics 
Amoxycillin pharmacokinetics were described with the following para-
meters: 
С = highest measured plasma concentration of each individual. 
Ц : calculated from the terminal part of the plasma amoxy­
cillin concentration curves i.e. from 4 hours after drug 
ingestion. 
AUC's : calculated with the trapezoid rule. 
T,
 0 , T 2 g.Tg 0 : indicate the period during which plasma concentrations, 
>1.0; 2.5; 5.0 pg/ml respectively, existed. 
For the steady-state situation during diflunisal medication, analogously, 
tiie C
max
 a n d C
min w e r e ^ 6 h ' ' 9 h e s t anc' t h e lowest measured intraindividual 
values, С . being the concentration just before the next dose. The appa-
m m 
rent Ц of D was calculated over the period between 4 and 12 hours after 
ingestion. 
Statistical analysis 
The student's paired t-test was used for statistical analysis of the 
data. Ρ values < 0.05 were accepted as statistically significant. All 
values are expressed as mean ± standard deviation. 
RESULTS 
The C
m a x
, t|, AUG and T1.0; T2.5; T5.0 after a single dose of 750 mg 
amoxycillin all increased significantly during coadministration of diflu­
nisal, as compared to the values obtained during a gift of amoxycillin 
alone (table I). These pharmacokinetic parameters did not change any 
further in the 4 volunteers, who received amoxycillin and diflunisal 
concommitantly during 4 days.The diflunisal steady-state pharmacokinetics 
were not significantly altered by a single dose of amoxycillin of 750 mg. 
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Tibie I Pharniecoklret^cs 4n volunteers (n-6) of emoxyd lin a/ter a single dose of 750 mg, 
without (A) and with (A*D) copconltant diflunlsel (0, 500 тд Ь 1 d ) administration 
The listed parameters are given as neans t SO "ne column "Increase ¡ ΐ )" gives the 
mean o f the intraindlvldually calculated percentLal Increases, a l l the differences 
Paraireter 
mtx 
t» 
AWC 
' 1 0 
"2 5 
T5 0 
(»9/1 
'm) 
'14 « 
¡nrs) 
(hrsi 
'hrs; 
) 
lrs/1) 
A 
11 3 Î 7 1 
1 2 t 0 г 
35 7 îzo г 
4 7 ; 1 1 
3 5 ! 1 1 
1 8 î 1 3 
A . D 
ie « 110 г 
1 s : 0 a 
7C β : 30 4 
9 5 = 1 8 
7 0 1 1 6 
5 0 t 1 4 
Increase (S) 
79 i 35 
62 í ЭО 
135 1 72 
119 .· 49 
109 î 54 
ш 
1
 no pccentuaPy described increase is given In 2 of the volunteers a level of Ь 0 jg/ml 
was not reached during A 
The С . values at day 6 were 156 t 29 mg/1 and the С 231 + 25 mg/l. 
min max 
At day 8 these figures were 169 ± 50 mg/1 and 238 + 35 mg/1 respectively. 
The apparent half-life was 18.1 ± 6.4 hours at day 6 and 19.1 t 5.3 hours 
at day 8. 
In the 4 volunteers who received diflunisal and amoxycillin concomnitant-
ly during 4 days, the plasma concentrations of diflunisal showed a slight 
fall (table II). 
We were not able to observe statistically significant changes in the 
excretion of diflunisal or its metabolites (table III). 
DISCUSSION AND THERAPEUTIC IMPLICATIONS 
Our results indicate that diflunisal partly inhibits the active renal 
elimination of amoxycillin leading to longer lasting effective plasma 
concentrations. For fixing thoughts, we used the levels 2.5 and 5.0 уд/ml, 
being the MIC (in vitro) for Proteus mirabilis and Escherichia coli res­
pectively (7) and 1.0 pg/ml (at least a factor 2.0 larger than the in vitro 
minimum inhibitory concentrations of amoxycillin against non-penicillinase 
producing Staphylococcus pyogenes and Streptococcus pyogenes, pneumoniae 
and faecalis; Ibidem). Anyhow, our observations excluded the opposite 
possible effect, of an enhanced renal elimination of the drug, leading to 
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Table II. Diflunisal (D) concentrations in 4 volunteers during a dose 
regimen of 500 mg b.i.d. and during coadministration of amoxy­
cillin (A) 750 mg b.i.d. on days 8-12 
drugs administered C
m i n C m a x 
(mg/1) (mg/1) 
day 6 D 140 + 19 227 + 29 
day 8 D + A 138 + 18 223 + 24 
day 12 D + A 1 1 7 + 8 213 + 31 
A s t a t i s t i c a l l y s i g n i f i c a n t (p < 0.05) f a l l in the С . was observed 
comparing the values obtained at day 12 with those of day 6 and 8. 
Table I I I . Twelve hours urinary recovery (mg) of unconjugated d i f l u n i s a l 
(D) and tota l d i f l u n i s a l (D + G; drug + i t s glucuronides; G expressed as 
mg d i f l u n i s a l ) in the same volunteers as in table I I . 
Day D D + G 
day б 38 Í 23 274 i 26 
day 8 62 + 35 304 ± 37 
day 12 60 ± 34 299 + 30 
impaired antimicrobial activity of treatment; still relatively high urinary 
levels of amoxycillin will continue to exist during combined medication 
with diflunisal, so the drug's value in treating urinary infections is not 
changed. The low toxicity of amoxycillin even at high concentrations ex-
cludes hazards of relative overdose of this drug by the combination with 
diflunisal. The diflunisal plasma concentrations on the other hand are not 
increased by the prolonged coadministration of amoxycillin, rather a small 
decrease was observed in the 4 volunteers who could be followed during 4 
days. The 2 other volunteers had to be withdrawn due to complaints of 
diarrhoea. Therefore the simultaneous use of both drugs does not seem to 
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increase the risk of accumulation of diflunisal and consequent 
intoxication with this drug. It cannot be excluded 
that the combined use might lead in some patients to ineffective non­
steroid treatment. The published data on steady-state levels of diflunisal 
500 mg b.i.d. in volunteers are contrasting. In volunteers Steelman at al. 
(8) report 88 mg/ml as mean value of С • , Dresse et al (2) report 123 ± 
23 mg/1. Given the capacity limited elimination of diflunisal and taking 
into account the levels reported by Steelman et al. for lower doses, ours 
and Dresse's steady-state concentrations are more on line of expectation. 
SUMMARY 
Regarding the realistic situation of NSAID treated patients, being in 
need of an antimicrobial cure, the possible pharmacokinetic interaction of 
diflunisal and amoxycillin - drugs both subjected to active tubular trans­
port mechanism in the kidney - was studied. In б young healthy volunteers -
during diflunisal medication - amoxycillin plasma peak levels were signi­
ficantly higher (79%), t\ significantly longer {62%), AUC greater (135%) 
and duration of period with defined plasma concentrations representing 
effective levels ( amoxycillin > 1.0; 2,5; and 5.0 pg/ml respectively) 
significantly longer than in the single drug condition. Diflunisal pharmaco­
kinetics were not significantly altered by a single dose of amoxycillin; 
prolonged coadministration of the antimicrobial produced a small decrease 
in diflunisal concentrations. It is discussed that these findings have no 
clinical consequences for the use of the antimicrobial during diflunisal 
treatment, whereas the NSAID's effectivity might be reduced due to lowered 
drug levels during amoxycillin medication. 
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INTRODUCTION 
Pharmacokinetics of new drugs are usually described with data obtained 
in young, healthy, (often) male volunteers. This statement also holds for 
the non-steroid anti-inflammatory drug (NSAID) diflunisal (1). The drug's 
pharmacokinetics are dose-dependent: due to capacity-limited elimination 
the plateau level is quite sensitive to changes in dose, the rate of eli­
mination (or: apparent Ц ) decreasing with increasing dose (2). This dic­
tates the need of individualisation of dosage in chronic regimens, whereas 
the fact that patients and not healthy subjects are medicated is still 
excluded from consideration. Some studies have demonstrated sex differences 
in the disposition of drugs; in animals the rat (3) has been extensively 
studied, and some reports describe sex differences in drug handling in the 
human (4, 5). Higher aspirinesterase activity has been found in males, in a 
comparison (6) of normal men and women. For diflunisal, a salicylic acid 
derivative, could be relevant the finding (7) of higher salicylic acid se­
rum levels in women compared with men after administration of a dosage cal­
culated per kg of body weight. We report data from a clinical trial on 
naproxen sodium versus diflunisal in rheumatoid patients and additional 
data obtained in male and female volunteers. 
METHODS 
D 
Commercially obtained tablets of 250 mg diflunisal (Dolobid , MSD Ltd., 
England) were used. Analytical grade reference substance was generously pro­
vided by the company. Reagents were of analytical grade, obtained from 
Merck (Darmstadt, GFR). Diflunisal concentrations were determined with a 
HPLC method (8). Of every aliquot of urine 1 ml was used for the diflunisal 
determination and another ml for the measurements of diflunisal and its 
glucuronides together . For the latter measurement the sample was adjusted 
to pH = 6.8, after which a 0.075 M phosphate buffer pH = 6.8 containing 
500 units of ß-glucuronidase was added. The mixture was then incubated for 
21 hours at 370C and subsequently processed (8). Albumin concentrations 
were assessed with a bromcresol green method (9). The patients received a 
dose of 500 mg diflunisal at 8.00 hr p.m. and 250 mg at 8.00 a.m.; in the 
first week only the dosage was 250 mg b.i.d.; all blood samples in the 
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patients were taken between 1.00 and 3.00 hr p.m. At the day of sampling 
the volunteers had been fasting overnight, and were given 500 mg diflunisal 
with a standard breakfast; in the volunteers samples were taken at 0, 20, 
40 and 60 minutes, and 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after ingestion. 
Patients had classical or definite rheumatoid arthritis according to the 
revised ARA criteria (10), and participated in the mentioned trial after 
informed consent. The volunteers gave their informed consent after full 
physical and laboratory examination as a check up for good health. Table I 
presents relevant vital statistics of patients and volunteers. 
Table 1 vital statistics of male ¡ч) and fenale (f) volunteers (v), and rneunatold parents (p), 
studied in a trial on diflunisal (0) versus naproxen sodiun (N) 
Number Subjects Drug Age (yrs) height weight body surface serjn alburlr serurr creatinine 
(enj (*S) (τ ; (g/1 {.nol/ , 
D 23 9Í3 ή 180Í11 70 9І9 7 I Bg+0 19 SE 9*4 5 О 8І10 1 
0 22 Sil 2 -70ifl 63 218 8 1 73*0 .3 49 6І2 7 7. 4*8 θ 
0 51 6І9 3 І 7 3 І 5 72 4Í.4 s 1 86*0 19 39 2І2 3 82 4Ï18 3 
D SI : n i 7 .60ÍS 65 4+13 0 . 68*0 17 39 3*3 5 65 6*9 1 
Ν 50 7-11 0 173;5 69 8*7 5 1 84:0 10 39 2*3 7 85 0: 0 6 
N 55 3Ϊ9 В 163*6 64 7Î1Û 6 1 бвіО 13 38 6Í3 5 74 5ÎÎ5 ? 
The following parameters to describe kinetics in the volunteers were 
used: 
С = highest measured plasma level of each individual. 
С
погт
 =
 ^ a x '
 m ul t''Pl 1' e d w i t h a "normalising" factor correcting for inter-
individual postural differences; this adjusting factor was the in­
dividual's body surface area (m2) divided by a standard body sur­
face (1.73 m 2) (nomogram for body surface in Wissenschaftliche 
Tabellen, Documenta Geigy, 7. Auflage was used). 
max 
AUG 
= time af ter ingestion at which С was reached. 
= area under the curve (calculated with the trapezoid rule) of plasma 
concentration versus time. 
Al l values obtained are presented as mean t standard deviat ion. The 
s t a t i s t i c a l s ignif icance of differences was investigated with two-sided 
Student's t-testing. 
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mean plasma 
cone ί S D ( m g / ι) 
130 
24 
time (weeks) 
Fig. 1. Plasma concentration of diflunisal throughout the trial. Differences 
between females and males are statistically significant (p < 0.05) in weeks 
1 through 18 for the real values, and in weeks 1 through 10 for the concen­
trations adjusted as a correction for postural differences to С , using 
norm
 J 
body surface areas (B.S.A.). 
RESULTS 
Figure 1 represents the mean plasma concentrations of diflunisal through­
out the trial. In women the concentrations are significantly higher in 
weeks 1, 2, 4, 6, 10, 14 and 18; after "normalisation" based upon individual 
body surface area the difference is still statistically significant in weeks 
1, 2, 4, 6 and 10. In table II the values in the volunteers are reported. 
In the female volunteers the mean maximal plasma concentration is signifi­
cantly (p < 0.05) higher than in the male; after correction for postural 
differences the difference is no longer significant. There are no differen­
ces between the two sexes (6 volunteers studied in each group) regarding u-
rinary recovery of unconjugated diflunisal and its glucuronides (table III). 
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Table II. Pharmacokinetics in male (n=8) and female (n=8) volunteers of 
diflunisal after a single oral dose of 500 mg (means + SD). 
parameter male female 
C
m a x
 (mg/1) 62.3 ± 12.6 77.2 + 11.3* 
C
norm
 ( n i 9 / 1 ) 6 8 · 0 ί 1 2 · 6 7 8 · 2 ± 9 · 4 
t i n a x (hrs) 4.0 І 1.4 3.8 + 1.3 
AUC (mg.hr.l"1) 1020 + 170 1290 t 150** 
Differences between male and female statistically significant: 
ρ < 0.05 and ρ < 0.01 respectively. 
Table III. Twelve hours and twenty-four hours urinary recovery (mg) of 
unconjugated diflunisal (D) and total diflunisal (drug + 
glucuronides: D + G; G expressed as mg diflunisal) in 6 male 
and 6 female volunteers after a single oral dose of 500 mg. 
period male female 
D D + G D D + G 
0-12 hr 18 ± 23 181 t 34 22 i 29 160 + 48 
0-24 hr 27 t 18 320 +46 32 + 25 345 ± 62 
DISCUSSION 
Our investigations have clearly shown apparent sex differences in the 
pharmacokinetics of diflunisal in man: mean plasma levels of the drug were 
significantly higher in the female than in the male individuals. This 
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difference was found in the single dose study in young volunteers, and in a 
clinical trial, during chronic medication with the drug, as well. 
The higher С of D in women in the single dose study might have been 
influenced by three factors. Firstly differences in absorption could exist 
between the sexes; in our study we did not measure gastrointestinal absorp­
tion, but data on different absorption in male versus female are not pre­
sent in the literature. Moreover, we found the same urinary recovery of D 
and its glucuronide in men and women. A modest difference in rate of eli­
mination, secondly, does no more provide a likely explanation: С „ is 
Шал 
reached at a time, where elimination does not make an important contri­
bution to D's disposition. Thirdly: after correction for body surface area 
the difference is no longer significant. This indicates that different 
apparent volumes of distribution should be the main factor explaining sex 
differences of С . It has to be mentioned, that the female volunteers 
and patients did not use oral contraceptive agents; these have been proven 
(5, 11) to influence drug disposition. 
The difference of plasma D levels between men and women during chronic 
medication in the clinical trial should mainly be ascribed to differences 
in the clearance of the drug: the plateau concentration is inversely pro­
portional with the - capacity limited - clearance. In the nature of things 
in the chronic treatment the difference persists after correction for indi­
vidual body surface area. 
The dip in the plasma levels between weeks 4 and 14 (fig. 1.) suggests 
induction of metabolism of D as has been demonstrated earlier for salicylic 
acid (12, 17). In this period of the trial returned tablet count did not 
indicate change in compliance. An equal compliance in both sexes is also 
demonstrated by the plasma levels of the other trial drug: naproxen concen­
trations (also measured with a HPLC method) were not different (fig. 2.). 
There was an over-intake of D in the male patients of 1.5 tablet per 
week after weeks 18 and 24. From that time on the sex difference in plasma 
levels is no longer statistically significant. 
Although no clinical implications have been ascribed (4, 5) to the 
metabolic sex difference regarding drugs, these are not beyond possibility 
regarding treatment with diflunisal: relative overdose might lead to toxic 
phenomena, and relative underdose might implicate lack of therapeutic res­
ponse. When "standard" dosages are used the risk for the toxic effect could 
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predominate in the female, and in elderly patients; the young male patient 
could be at risk for under-treatment. We have been able to demonstrate a 
relation for the plasma level of diflunisal and its hypouricemic effect 
(14) and the Ritchie index in RA patients (J.W.A. van Loenhout et al.: to 
be published, see chapter IV). This stresses the necessity of dose adapta-
tion, using no "standard dosage": plasma level monitoring might be ad-
visable in this respect. 
mean plasrna 
cone ïSD (mg/ l ) 
naproxen-sodium 825 mg daily 
real concentration 
adjusted lorBSA 
-τ—ι 1 τ­
ι 2 и 6 It, 
tinne (weeks) 
Fig. 2. Plasma concentration of naproxen throughout the trial, showing no 
difference between males and females. 
SUMMARY 
Apparent sex differences in diflunisal metabolism were studied in 
rheumatoid patients and in volunteers. In the patients plasma levels were 
measured at control visits during a 24 weeks clinical trial on naproxen 
sodium versus diflunisal; in the volunteers a single dose study with 500 mg 
orally was made with determinations in plasma and urine. Statistically 
significant differences in the volunteers were ascribed to different ap­
parent volumes of distribution, due to postural sex differences; upon 
chronic medication the difference in the drug's plateau level is attributed 
to the capacity limited clearance of this salicylic acid derivative in 
patients with again postural differences. Given the risk of relative over­
dose (in female or geriatric patients) or undertreatment (in men) 
respectively, individualised dosage annex plasma level monitoring for the 
drug are recommended. 
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Discussion and conclusions 
91 

DIFLUNISAL VERSUS NAPROXEN SODIUM IN THE TREATMENT OF PATIENTS WITH 
RHEUMATOID ARTHRITIS 
As discussed in chapter I, the continuing search for new NSAID 
finds its justification in the considerable interindividual 
differences in the response of RA patients to NSAID treatment, even 
despite comparable disease activity. The data reported in chapter IV 
on the comparison of diflunisal (D; a salicylic acid derivative not 
previously been studied in long-term trials in RA) with the referen-
ce drug naproxen (used in the form of its sodium salt, NS, likewise 
not previously studied in long-term trials in RA) show that the two 
drugs are equally effective in the chosen dose of 750 mg D and 825 
mg NS daily. As discussed in chapter IV and VII, however, we tend to 
prefer NS in view of its pharmacokinetic properties. Larger doses 
of NS do not result in accumulation, because saturation of plasma 
protein-binding sites results in more rapid elimination of the 
(non-protein-bound) drug; in contrast. D has a capacity-limited 
elimination pattern, with the risk of accumulation and the necessity 
of plasma level monitoring.With respect to side effects, our data 
indicate that NS, as naproxen itself, can indeed give rise to gastro-
intestinal complaints. 
LONG-TERM CLINICAL TRIAL 
We have opted for a long-term trial because one aim of the study 
was to approximate what happens in the treatment of RA. Pertinent 
questions in this respect are: do two drugs more or less comparable 
as to effectiveness and side effects in short-term use, remain so 
in long-term treatment? Does one drugs have special (dis) advan-
tages which become apparent only during long-term use? How can the 
data obtained be translated into practical advice for treatment? 
The science of the clinical trial is still in development, and most 
of the knowledge has been obtained from short-term studies. The pre-
sent long-term trial affords the opportunity to answer (also) addi-
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tional fundamental and practical questions concerning long-term 
RA treatment as well as the science of trials. A number of them have 
been formulated in chapter I and will be discussed hereafter. For the 
moment, it should be stressed that conclusive remarks, apply only 
to the two NSAID studied. 
REDUCTION OF DISEASE ACTIVITY AS A FUNCTION OF THE INITIAL VALUE; 
CONSLQUENCES FOR TREATMENT 
A remarkable conclusion of our study is that both D and NS reduce 
disease activity proportionally with respect to most of the para­
meters. With respect to initial (I) and final (F) disease activity 
and its change(<5) during treatment, the following equations can 
be made: 
(1) F = K.I and 
(2) 6 = 1 - (K.I) = (l-K)I 
In the case of non-proportional reduction of disease activity by 
an absolute quantum (A), the equations were as follows: 
(3) F = I - A 
(4) 6 = 1 - (I-A)=A 
In (4), θ is completely independent of I; nevertheless, in both 
situations F = f(I). The value of К in (1) in the trial described 
in chapter IV is approximately 50%. This would mean that for the 
two NSAID studied an initial Ritchie index of 35, and a morning stiff­
ness < 4 hours represent the maximum disease activity that justifies 
treatment of up 6 months' duration with NS or D only. The final 
disease activity in this case would be somewhat upwards of 15, 
corresponding with Steinbröcker's functional class ?.. 
It is a striking fact that virtually no data exist on a more 
precise definition or description of disease-related abnormalities 
in terms of inflammatory (and therefore potentially reversible) and 
irreversible changes (destructive lesions and fibrosis as a 
consequence of inflammation). This would of course, be very helpful 
in selecting patients for clinical trials in inflammatory diseases 
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such as RA and , in addition, in selecting useful parameters of 
inflammatory disease activity. Possibly, future studies on the effect 
of second-line antirheumatic drugs may supply information in this 
respect and, for instance, indicate differences between pain as a 
result of inflammation and that due only to destruction and 
deformity.On page 96 we will discuss a parameter for which δ = f(I) 
depends both on inflammatory activity and irreversible damage 
already present, to illustrate this problem. 
F = K.I; POSSIBLE CONSEQUENCES FOR NSAID TRIALS 
Considerations as described on page 92 have consequences not only 
for the choice of a particular drug in medical practice but also for 
the formulation of criteria for admission of RA patients to NSAID 
trials. With the assumption that our data on NS and D can be genera­
lised, they indicate, in addition to minimum disease activity crite­
ria as defined by the Cooperative Clinics Study Group, that maximum 
disease activity criteria should be defined.This would prevent admis­
sion to a trial of patients with excessive disease activity,obviously 
of benefit to patient and investigator alike. As described in 
chapter IV, the drop-outs in this trial all had an ESR in excess of 
65 mm; this and the already mentioned Ritchie index value of 35, 
and a morning stiffness > 4 hours, can be used as criteria for 
maximum disease activity in a trial with drugs of this type. A 
further point to be raised is the desirability of an interim eva­
luation. For instance, if during a trial of another NSAID against 
D or NS in the dosage used in the present study, an interim overall 
evaluation would indicate less than 50% reduction of disease 
activity, then premature termination of trial should be considered. 
LONG-TERM VERSUS SHORT-TERM NSAID TRIAL IN RA 
It seems appropriate to determine the value of NSAID, with a 
proven effect on painful conditions such as postepisiotomy pain, 
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post-meniscectomy pain or postoperative pain in oral surgery for the 
treatment of RA in a short-term study (order of magnitude: 2 weeks). 
On the other hand, data shown in chapter IV (obtained from a long-
term trial which of necessity comprised short-term trial results) 
indicate that 
a. clinical effectiveness can increase after two weeks of NSAID 
treatment. 
b. an initial superiority of one drug (D at week 6 and 10) can be 
transient 
c. if auto-induction of drug metabolism exists (as is probably the 
case with D, see chapter VII), then this may result in a decrease 
in clinical effectiveness (the trial patient may respond by over-
intake of the drug, see chapter VII). 
d. side effects are equally distributed over the entire long-term 
trial period, and a trial of this duration therefore gives a 
better impression of the range and frequency of side effects than 
a short-term trial (table III, chapter IV). It should be mentioned 
that side effects characteristic for one particular drug (e.g. 
tinnitus due to salicylates) always and inescapably affect the 
double-blind situation. No adequate solution to this problem has 
so far been found. 
THE VALUE OF THE PARAMETERS USED 
One may be inclined to regard the lack of significant correlations 
between the individual parameters in most instances (as mentioned 
in chapter IV) as an argument for their inadequacy to reflect RA 
disease activity and therefore against their usefulness as disease 
activity parameters. However, we tend to prefer the view that this 
fact rather reflects the wellknown considerable variability in 
clinical expression of the disease entity RA, which itself is a 
syndrome without pathognomonic signs or symptoms. This view leads 
to two further conclusions: 
a. the parameter best correlating with the others should probably 
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be used as selection criterion, measure for interim evaluation, 
and aid in comparison with data from other studies; it has been 
shown in chapter IV that, in our study, the Ritchie index was of 
the greatest value in this respect. 
b. multivariate analysis, parametri cally taking into account the 
relative differences in the course of each parameter, is the 
method of choice to make an overall compari son.between two treat­
ment groups. 
(CO-)VARIATE CORRECTION; OVERALL COMPARISON 
The proven relation between the value of a parameter at a certain 
moment during the trial and its initial value ( a percentual reduc­
tion) is also characterized by a correlation coefficient which 
(squared) determines the extent to which the relation may be used 
to correct for the initial imbalance between the two treatment groups 
in subsequent evaluationsrvariate correction. An additional correc­
tion (be it small) for initial imbalance can be carried out by impli­
cating the (small) correlation of the parameters: co-vari ate correc­
tion. An obvious method to compare both treatment groups would have 
been analysis of pairs; however pair matching on the basis of Ritchie 
index and ESR resulted in 2 groups of only 14 patients, who occa­
sionally even showed significant differences (as expected) with res­
pect to other parameters. In the present study we made an overall 
comparison in such a way that (parametrically) the magnitude of 
group differences per parameter was counted, to prevent a small 
difference in one parameter from being as important as a big dif­
ference in another. In hotelling's Τ test, which was used, all para­
meters have equal importance. Our data do not warrant conclusions as 
to the optimal number of parameters to be used in a RA trial; how­
ever, the question of how to achieve optimal detection of the effect 
of treatment with a minimum number of parameters (and therefore 
with a minimum work-load) remains a valid one which, we hope, will 
be answered in the future. 
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INFLUENCE OF THE DISEASE STAGE ON 6 
Roth thp normal physiological maximum value of a parameter (e.g. 
"normal grip strength"; I = 100) and the degree of irreversibility (e. 
g. "totally lost grip strength" 1=0) determine the extent to which 
certain parameters are able to change during treatment. A (still) 
normal joint function will not improve during treatment (e.g. when 
I = 100%, ó grip strength = 0) and the same applies when residual 
joint damage without inflammation exclusively determines joint 
function. In this case the equation δ = f(I) can be represented by 
a curve: the span of curve (s) determines the extremes 1=0 and 1= 
100%, the height (h) represents the maximum δ for this parameter. 
A parameter such as grip strength, for which δ = f(I) is determined 
in this imperfect way, can at best be partially useful in a clinical 
trial in which most admission criteria and the parameters obey the 
equations δ = (l-k)I and F = к.I (this does not necessarily reduce 
the value of the parameter as an intra-individual measure of disease 
activity during the treatment). 
grip strength 
г 
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PHARMACOKINETICS AND RELATION BETWEEN PHARMACOKINETICS AND 
PHARMACODYNAMICS 
One reason for considering pharmacokinetic measurements (notably 
plasma level measurements) during a clinical trial is the need to 
verify drug compliance. Generally and in our study also, the value 
of this check is at best modest. Plasma naproxen concentrations give 
no information on adequate intake of the drug over a prolonged 
period: single intake and regular intake give the same result. This 
is different for diflum'sal, as indicated by lower plasma concen-
trations after a single dose (table II, chapter VII) than after 
"semichronic" (table II, chapter VI) and chronic (chapter IV) 
administration of the drug. The accumulation of this drug, reaching 
a plateau plasma concentration after several days, affords some 
possibility to verify drug compliance. However, a really good marker 
for drug compliance in fact does not exist; the returned tablet 
count (counting the tablets not used in the preceding period) is not 
entirely reliable either. Apart from that, the rise in diflunisal 
plasma levels in male patients at week 18 and 24 of the trial pro-
bably reflects a slight over-intake of this drug with capacity-
limited elimination. 
An interesting finding in our study was the decrease in plasma 
diflunisal concentrations at week 4 tot 14 of the trial (chapter 
VII), which probably indicates auto-induction of drug metabolism, 
of the kind demonstrated for salicylic acid. A direct relationship 
between plasma drug levels and therapeutic effect was not found 
consistently, either interindividually or intraindividually. For 
diflunisal, however, occasional relations were found: the Ritchie 
index was on several occasions significantly correlated with plasma 
concentrations (chapter IV) and there existed some relation between 
CNS side effects (fig, 3, chapter IV) and plasma concentrations, and 
between hypouricemic effect (fig. 1, chapter V) and plasma drug 
levels. As already mentioned, one possible disadvantage of difluni-
sal as a drug for chronic administration lies in its pharmaco-
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kinetics, with the risk of accumulation (chapters IV and VII). The 
measurement of plasma concentrations of drug is a time-consuming 
procedure which makes it desirable to start these determinations 
while the trial is still in progress.A practical method is to have 
an outsider not involved in the trial but familiar with the code, 
change the numbering of a cohort of samples;this ensures that it 
remains unknown to which patient the sample belongs, but its drug 
concentration can be determined and used for certain purposes. At 
the end of the trial this laborious part of the laboratory effort 
is nearly finished, and measurements can be allocated to the indivi-
dual patients. 
* We are grateful to Miss H.L.M. Siero for her help in this respect. 
HYPOURICEMIC EFFECT OF DIFLUNISAL 
Serum uric acid concentrations determined in the RA patients 
indicate that diflunisal, but not naproxen sodium, has a hypouri-
caemic effect. This effect persisted throughout the period of treat-
ment with this drug (chapter V). Since we made this observation, 6 
gouty patients have been treated with diflunisal, resulting in the 
lowering of a mean uric acid concentration of 0.54 + 0.12 mmol/1 to 
0.41 + 0.11 mmol/1 after two weeks. In two of these patients therapy 
was started during an acute gouty attack, leading to prompt and 
sufficient reduction of pain and joint swelling. Diflunisal may 
afford interesting possibilities for the treatment of gout, since 
it has analgesic and antiphlogistic properties as well as a per-
sistent hypouricanric effect. 
INTERACTION OF DIFLUNISAL AND AMOXYCILLIN 
Since it is conceivable that RA patients treated with diflunisal 
may sooner or later need antibiotic treatment - in fact RA patients 
are more prone to develop bacterial infections - we decided to study 
possible interactions between diflunisal and amoxycillin, a widely 
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used antibiotic. Since both drugs are subject to active tubular anion 
transport mechanisms in the kidney, a mutual influence on their 
pharmacokinetics was expected,3nd.indeed, found (chapter VI). Uur re-
sults indicate that this has no clinical consequences for the use 
of amoxycillin; this interaction may indeed result in a slightly 
diminished effectiveness of diflunisal (table II, chapter VI), but 
data so far available are certainly not sufficient to advise a 
higher dosage of diflunisal in this situation. 
SIDE EFFECTS OF THE NSAID 
Apart from what has been said on side effects on page 56 it 
should be noted that the number of drop-outs in the present trial 
was small. This saved us the trouble of working out how to handle 
the data on the remaining patients; this would have been even more 
troublesome if drop-outs had been predominantly confined to one 
group. 
In terms of the profile of adverse effects we found, as expected, 
a significant number of CNS side effects in the diflunisal-treated 
group (table III, chapter IV), showing some relationship with plasma 
diflunisal concentrations (fig. 3, chapter IV). The length of the 
period during which the patient is exposed to certain plasma concen-
trations of the drug may be important in this case, for these side 
effects were not observed during short-term use in volunteers with 
even higher mean plasma drug concentrations (table II, chapter VI). A 
more likely explanation is that in this group differences in side ef-
fects are related to the lower serum albumin concentrations and there-
fore higher non-protein-bound drug concentrations in the RA patients 
(table I, chapter VII). 
The mode of presentation of side effects (table IV, chapter IV; 
side effect per patient, per date of reporting) affords an excellent 
possibility to keep this facet of a trial up to date and to have 
relevant information before the end of the blind phase of the study. 
Thus it was possible to establish, while the trial was still in 
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progress (weeks 2, 4, 6, 10, 14, 18 and 24), that the incidence of 
reported side effects (6, 3, 9, 9, 8, 10 and 6 instances, res-
pectively) did not change significantly. 
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HOOFDSTUK IX 
Slotbeschouwingen 
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DIFLUNISAL VERSUS NAPROXEN SODIUM IN DE BEHANDELING VAN PATIENTEN 
MET RHEUMATOIDE ARTHRITIS 
Zoals in hoofdstuk I werd besproken, vindt het speuren naar steeds 
weer nieuwe NSAID een rechtvaardiging in de interindividueel geheel 
verschillende respons van patiënten met vergelijkbare "ziekte-aktivi-
teit", gedefinieerd naar en bemeten met thans geldende inzichten, 
respectievelijk meetmethoden. Het in hoofdstuk IV gerapporteerde 
over de vergelijkingen van diflum'sal (D; een salicylzuur-derivaat, 
dat nog niet langdurig bij RA werd onderzocht) met de referentiestof 
naproxen (NS; een bij RA beproefd NSAID, in de vorm van het nog niet 
eerder langdurig bij patiënten met RA gebruikte natriumzout) laat 
zien dat de twee farmaca een gelijke effektiviteit bezitten bij de 
gekozen doseringen van 750 mg D en 825 mg NS per dag. Op grond van 
de farmacokinetiek van deze twee NSAID wordt in hoofdstuk IV en VII 
geconcludeerd tot een voorkeur voor naproxen. NS neigt niet tot 
cumulatie, wordt integendeel bij hogere doses/concentraties door 
steeds meer verzadigd geraken van plasma-eiwit-bindingsplaatsen 
juist versneld geëlimineerd; D volgt een capaciteits-beperkt-eli-
minatie-patroon, met kans op cumulatie en noodzaak tot "plasma level 
monitoring". NS bleek overigens (evenals naproxen zelf) toch niet 
vrij van gastro-intestinale nevenwerkingen (tabel III, chapter IV). 
LONG-TERM CLINICAL TRIAL 
Voor deze vergelijkende studie werd een trial-duur van 24 weken 
gekozen: het doel was immers niet een kortdurende vergelijking op 
NSAI-potency in meer algemene zin, maar een zo goed mogelijke re-
presentatie van de situatie in de behandeling van RA. Daarbij gel-
den vragen als: blijven twee min of meer evenwaardige stoffen langer 
dan enkele weken gelijk in werking en nevenwerkingen, heeft één 
middel eventueel bijzondere voordelen of nadelen die pas op termijn 
waarneembaar zijn, en hoe kan het aldus waargenomene met een rede-
lijke zekerheid worden vertaald naar een praktijkadvies. Daar de 
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wetenschap van de clinical trial.meer sensu stricto de geneesmiddel-
trial bij RA-patienten, nog volop in ontwikkeling is, kan een onder­
zoek van deze duur ook het antwoord leveren op een aantal meer fun­
damentele vragen, zowel betreffende de RA-therapie als de trial-we­
tenschap. Een reeks van dergelijke vraagpunten werd in het hoofdstuk 
I geformuleerd, en wordt in het navolgende besproken. Een voorbehoud 
dat hierbij gemaakt dient te worden, is dat veralgemening van de te 
presenteren conclusies pas zal mogen geschieden, wanneer analoog 
onderzoek over andere NSAID vergelijkbare antwoorden op deze vragen 
biedt. 
REDUKTIE VAN ZIEKTE-AKTIVITEIT ALS FUNKTIE VAN DE BEGINWAARDE; 
CONSEQUENTIES VOOR DE THERAPIE 
Een naar onze mening waardevolle conclusie van de vergelijkende 
studie van D en NS is, dat de beide farmaca de ziekte-aktiviteit, 
voor wat betreft de meeste parameters proportioneel reduceren; 
heet de beginwaarde van ziekte-aktiviteit I; de eindwaarde F, de 
verandering δ, dan geldt dus: 
(1) F ƒ k.I, en 
(2) 5 = 1 - (k.IHl-k)I 
In geval van reduktie met een absoluut quantum (A) zal e.e.a. 
luiden: 
(3) F = I-A, 
(4) & = I-(I-A)=A. 
In (4) is δ geheel onafhankelijk van I; in beide situaties geldt 
overigens dat F = f(I). De waarde van к in (1) in de in hoofdstuk 
IV beschreven trial is ongeveer 50%. De consequentie hiervan is dat 
voor deze twee NSAID een initieel niveau van 35 op de pijnschaal 
van de Ritchie-index (en een ochtendstijfheid van de gehele ochtend 
c.q. maximaal 4 uur) de maximum ziekte-aktiviteit aangeven welke 
nog het plannen van een behandeling met alleen NS of D gedurende 
een half jaar rechtvaardigt : de gemiddelde (cave!) patient belandt 
dan t.z.t. op een eindwaarde van de Ritchie-index van ruim 15, over-
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eenkomende met een funktionele classificatie van klasse 2 volgens 
Steinbröcker. 
Het lijkt vooralsnog schijnprecisie uit formule (1) en (2) te con-
cluderen dat de klinische indruk:dat bij een licht geval van RA NSAID 
therapie afdoende is om de ziekte-uitingen geheel te onderdrukken. Dit 
is slechts mogelijk indien (3) en (4) gelden en I < A. 
Het is opvallend dat noch de klinische literatuur betreffende RA, 
noch de rapportage over geneesmiddelen-trials bij RA, uitspraken moge-
lijk maken omtrent het precieser definiëren van ziekte-uitingen op het 
beginmoment van een behandeling (louter pijn, i.e. alleen -itis; -itis 
met tevens erosieve veranderingen; vergevorderde veranderingen met 
irreversibel funktieverlies) in vergelijking met die op een later 
tijdstip. Mogelijk zullen de studies omtrent major antirheumatica wel 
conclusief zijn betreffende de vraag naar b.v. het verschil tussen 
"pijn t.g.v. alleen ontsteking" en "pijn t.g.v. destruktie of defor-
matie". Op blz. 108 wordt gepoogd voor een parameter, waarvoor 6 = 
f(I) afhangt van zowel ziekte-aktiviteit als restschade, dit probleem 
nader toe te lichten. 
F = k.I; CONSEQUENTIES VOOR NSAID TRIAL 
Het hierboven beschrevene heeft niet alleen consequenties voor de 
practicus t.a.v. de therapiekeuze maar evenzo voor de trialist bij 
het formuleren van toelatingscriteria voor een NSAID trial bij RA, 
verondersteld dat de omtrent D en NS gedane bevindingen veralge-
meend mogen worden. Dit betekent dan een aanvulling: een norm be-
treffende maximum ziekte-aktiviteit, naast het door de Cooperative 
Clinics Study Group geformuleerde minimum als toelatingscriterium. 
Hantering van dit maximum voorkomt toelating van patiënten met een 
te grote initiële ziekte-aktiviteit, met alle hinder voor de pa-
tient en overbodige onderzoekerstijd vandien. 
De drop-outs in de in hoofdstuk IV beschreven trial hadden een 
BSE groter dan 65 mm; deze, en de genoemde Ritchie-index boven 35, 
en een als maximum gedefinieerde ochtendstijfheid van 4 uur, kunnen 
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dus funktioneren als norm van inaximaal toelaatbare ziekte-aktiviteit 
bij entrée in de trial. 
Zou bij selectie conform het gesuggereerde in een trial betref-
fende een NSAID t.o.v. D of NS in de door ons gebruikte dosis de 
reduktie van ziekte-aktiviteit van alle trial-patienten bijeen, tus-
sentijds geëvalueerd, beduidend minder zijn dan 50%, dan ware te 
overwegen de trial voortijdig af te breken bij tussentijdse evalua-
tie. 
LONG-TERM VERSUS SHORT-TERM TRIAL VAN NSAID IN RA 
Het is voor de hand liggend dat NSAID die in de gebruikelijke 
klinische modellen bruikbaar zijn gebleken voor de behandeling van 
situaties als post-episiotomie pijn, post-menisectomie pijn of 
"post-surgical pain" in de kaakchirurgie, eerst kortdurend (grootte-
orde: 2 weken) worden beproefd op hun waarde voor de therapie van 
RA. Anderzijds illustreren de in hoofdstuk IV beschreven trial-
bevindingen (uit een long-term trial die peildata bevatte welke een 
short-term trial inbouwden!): 
a. een effect kan nog toenemen na twee weken NSAID medikatie. 
b. een aanvankelijke superioriteit van één middel (D bij metingen 
na 6 en 10 weken) kan voorbijgaand blijken. 
с bestaat auto-inductie t.a.v. geneesmiddel-metabolisme (wellicht 
geldend voor D, en - gezien het verdere metabolisme en enige mate 
van relatie plasmaspiegel-effekt voor dit middel - het meest 
kritisch bij de mannelijke patiënten; zie hoofdstuk VII)-dan zal 
daardoor het effekt kunnen afnemen (en de trial-patient tot 
overintake van het farmacon komen; weer: zie hoofdstuk VII!). 
d. bijwerkingen zijn gespreid over de hele long-term trial periode, 
en voor een behoorlijk zicht hierop is langer durende observatie 
zeker noodzakelijk (tabel III in hoofdstuk IV). Opgemerkt moet 
worden, dat zeer specifieke stof-gebonden nevenwerkingen, die de 
dubbelblind-situatie benadelen (zoals oorsuizen t.g.v. salicyla-
ten), moeilijk als verbrekers van de dubbelblinde opzet van een 
studie te omzeilen zijn. 
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DE WAARDE VAN DE GEBRUIKTE PARAMETERS 
Men zou geneigd kunnen zijn de geringe, veelal niet statistisch 
significante correlatie van de diverse parameters (zoals gemeld in 
hoofdstuk IV) als een diskwalificatie te zien: moet men ze niet als 
onbruikbaar verwerpen voor het in goede samenhang beschrijven van 
een groep patiënten tijdens een behandeling voor RA ("de" ziekte)? 
Een betere visie lijkt, deze geringe correlatie niet als bewijs van 
armoede te zien, doch te beschouwen als een logische consequentie 
van de zeer variabele klinische expressie van het ziektebeeld in 
individuele patiënten (niet "de" ziekte, doch een syndroom). Aan 
deze opvatting zijn twee verdere gevolgtrekkingen te verbinden: 
a. de toch nog het best met de overige parameters correlerende 
parameter heeft waarschijnlijk de meeste waarde als selectienorm, 
maat voor tussentijdse evaluatie, en hulpmiddel ter vergelijking 
met gegevens van elders; in hoofdstuk IV werd getoond dat de 
Ritchie-index deze speciale plaats verdient. 
b. een multivariant analyse, waarin parametrisch de relatieve ver-
schillen in het verloop van elke parameter worden betrokken, is 
de aangewezen weg om een overall vergelijking uit te voeren. 
(CO-)VARIANTIE-CORRECTIE; OVERALL-VERGELIJKING 
De bewezen relatie tussen de waarde van een parameter op een mo-
ment tijdens de trial en diens initiële waarde (telkens een procen-
tuele reduktie) wordt tevens gekarakteriseerd door een correlatie-
coëfficiënt, die (gekwadrateerd) bepaalt in hoeverre de relatie 
mag worden benut voor het verwerken van de "imbalance" tussen de 
twee behandel ingsgroepen aan het begin van de trial,іп de beoorde­
ling op latere tijdstippen: variantie-correctie. Tevens is nog enige 
aanvullende verdiscontering van deze initiële imbalance mogelijk 
door de (zoals gezegd geringe!) correlatie van de onderzochte para-
meter met de andere parameters ter correctie in de beoordeling te 
benutten (co-variantie-correctie). 
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Een voor de hand liggende methode van vergelijking van de beide 
behandelingsgroepen had paars-gewijze analyse kunnen zijn: een paren-
matching op basis van de Ritchie-index en BSE leverde evenwel (na 
het in hoofdstuk IV en op blz. 56 gemelde.niet onverwacht!) twee 
groepen van slechts 14 patiënten, die t.a.v. andere parameters soms 
zelf statistisch significant verschilden. Het was daarom wenselijk 
tot overall-vergelijking te komen op een wijze die (parametrisch!) 
de grootte van de groepsverschillen per parameter telde, zodat niet 
een klein verschil in één parameter even zwaar zou wegen als een 
groot verschil in een andere. In de gebruikte Hotelling's Τ test 
werden de afzonderlijke parameters elk als even belangrijk geteld. 
Het is ondoenlijk aan de eigen gegevens conclusies omtrent een 
optimaal aantal parameters in een RA trial te verbinden; de vraag 
naar een mogelijkheid tot optimale detectie van effekten van behan­
deling bereikt met een minimum aantal parameters (en minimum work­
load) is een essentiële, die de toekomstige ontwikkeling van de 
tri al-wetenschap zal moeten oplossen! 
INVLOED VAN HET ZIEKTESTADIUM OP δ 
Het laat zich raden, dat het normale physiologische maximum 
(b.v. "normale knijpkracht", I = 100%) en de irreversibele rest-
schade t.g.v. RA (b.v. "geheel verloren knijpkracht"; I = 0) grenzen 
stellen aan de mate, waarin bepaalde parameters van de ziekte kunnen 
veranderen. Een patient met een nog onbeschadigde funktie van een 
gewricht zal niet super-normaal worden dankzij een therapeutische 
maatregel (b.v. bij I = 100%: δ knijpkracht = 0 ) , maar ook zal 
δ = 0 gelden in een geval waarin geen verbetering meer te verwachten 
is. Dergelijke 6 = f(I) kan men zich voorstellen als een kromme: 
de koorde van de kromme (s) geeft de genoemde uitersten van I = 0 
en I = 100% aan, de hoogte (h) de grootst haalbare δ voor deze para­
meter. Een parameter waarvoor déze δ = f(I) geldt ,zal ook gezien 
de grote interindividuele verschillen in I (1-100) slechts be­
perkt bruikbaar zijn in een klinische trial, waarin de op de RA 
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betrekking hebbende toelatingscriteria garanderen dat voor alle of 
de meeste andere parameters δ = (l-k)I en F = k.I gelden (hetgeen 
niets afdoet aan de waarde van de parameter als intraindividuele 
maat tijdens ziektebehandeling). 
knijpkracht 
O 25 50 75 100 
ALS % VAN DE MAXIMALE INITIËLE WAARDE 
PHARMAKINETIEK EN RELATIE TUSSEN PHARMAKINETIEK EN PHARMACODYNAMIE 
Een eerste reden waarom men tijdens een klinische trial pharma-
cokinetische metingen (en met name plasmaspiegel-metingen) kan 
overwegen, is ter controle van de geneesmiddel-compliance; in het 
algemeen en ook in ons geval valt de waarde van deze check tegen. 
Voor naproxen is niet aan de plasmaconcentratie af te lezen, hoe 
over een aantal dagen de intake is geweest: eenmalige inname en ge-
regelde inname volgens voorschrift leveren dezelfde uitkomst! 
Voor diflunisal ligt dit anders; men vergelijke de plasmaconcentra-
tie bij vrijwilligers, zoals gemeld in tabel II van hoofdstuk VII 
(na een eenmalige orale dosis van 500 mg r bij mannen = 62,3 + 
12,6 mg per liter en 77,2 + 11,3 mg/l bij vrouwen) met die in tabel 
II van hoofdstuk VI (tijdens - semichronisch - tweemaal daags 500 
mg per os; С . = 140 + 19 mg/l) en met die, welke in de trial van 
hoofdstuk IV bij patiënten werden gevonden (min of meer met min 
111 
vergelijkbare waarden, zoals weergegeven in figuur 1 van hoofdstuk 
VII). Het cumuleren van dit farmacon, met een plateau-plasmaconcen-
tratie na enkele dagen gebruik, levert enige controle-mogelijkheid 
op compliance. Een echt goede marker van compliance is in feite 
niet voorhanden; de "returned tablet count" (met telling van het 
restant medikament in de trial-verpakking van de voorbije trial-
periode) biedt evenmin een gegarandeerd sluitende controle. Het 
leek overigens niet te gedurfd de diflunisal-concentratie-stijging 
bij de mannelijke patiënten op weken 18 en 24 van de trial (fig. 1, 
hoofdstuk VII) toe te schrijven aan overintake van het middel met 
capaci teitsbeperkte eliminatie in deze periode. 
Een interessante bevinding was voorts dat de daling van de diflu-
nisal-concentratie in de weken 4-14 van de trial (hoofdstuk VII) het 
waarschijnlijk maakt, dat evenals voor salicylzuur, bij chronisch 
gebruik ook voor diflunisal auto-induktie van het metabolisme aan de 
orde is. Een rechtstreekse relatie tussen plasmaspiegels en thera-
peutisch effekt, steeds geldend, ook binnen individuen, en bij voor-
beeld bruikbaar om bij een deel van non-responder-patienten de thera-
pie bij te stellen, werd niet gevonden (en was ook niet verwacht). 
Voor diflunisal werden wel enkele relaties tussen pharmacokinetiek 
en pharmacodynamie gevonden: Ritchie-index bleek enkele malen sig-
nificant gecorreleerd met de plasmaconcentraties (hoofdstuk IV). Er 
was enige relatie tussen C.Z.St.-nevenwerkingen en de plasmaconcen-
tratie (fig. 3 van hoofdstuk IV) en tussen de hypouricemiserende 
werking en de pharmaconconcentratie (figuur 1 van hoofdstuk V ) . Daar-
naast geldt voor diflunisal de farmacokinetiek van deze stof juist 
als een mogelijk bezwaar bij het gebruik in de praktijk van alledag 
(zie slot van de discussie van hoofdstukken VI en VII). Het meten van 
de plasmaconcentraties van farmaca vergt tijd,zodat men bij voorkeur 
dit werk alvast tijdens de trial zou willen verrichten. Een prak-
tische methode is de nummering van patiënten-samples, steeds nadat 
een aantal is verzameld, door een de code kennende buitenstaander* 
te doen wijzigen: het blijft dan onbekend van welke patient het sample 
stamde, maar wel wordt bekend welk geneesmiddel het bevat. Op 
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het eind van de trial is dit bewerkelijke deel van de laboratorium-
bezigheden dan vrijwel gereed, en kunnen de opgespaarde meetgegevens 
aan de betreffende patiënten worden toegekend. Het is bovendien denk-
baar dat de aldus eerder beschikbare gegevens aanleiding zijn voor 
aanpassing van het onderzoek en de dubbelblinde code blijft onverlet. 
* Terzake moge Mej. H.L.M. Siero voor haar accurate hulp tijdens de 
trial worden bedankt. 
HYPOURICEMISERENDE WERKING VAN DIFLUNISAL 
Doordat - in de verwachting van een hypouricerniserende werking 
van het salicylzuur-derivaat - metingen van het urinezuurgehalte 
bij de RA - patiënten in het protocol van de trial waren opgenomen, 
kon inderdaad een hypouricerniserend effekt van dit middel worden 
aangetoond, zoals in hoofdstuk V werd beschreven. 
Inmiddels zijn 6 patiënten met jicht onder behandeling met diflu-
nisal. Bij hen daalde het gemiddelde urinezuurgehalte in twee weken 
van 0.54 + 0.12 mmol/1 tot 0.41 + 0.11 rnmol/l. Bij twee van deze 
patiënten werd de therapie gestart tijdens een acute aanval, waarbij 
ook prompte en afdoende afname van pijn en zwelling bleken. Voor de 
behandeling van jicht biedt diflunisal wellicht een interessante 
mogelijkheid tot het bewerkstelligen van hypouricemie door chronische 
medikatie èn van analgesie en anti-inflammatoir effekt in de acute 
situatie. Het aantal aldus behandelde patiënten zal in de toekomst 
daarom worden uitgebreid 
INTERACTIE VAN DIFLUNISAL EN AMOXYCILLINE 
Daar het niet onrealistisch is te veronderstellen dat menige 
met diflunisal behandelde patient met RA ooit een antimicrobiële 
kuur met een penicilline zal ondergaan, werd besloten tot de in 
hoofdstuk VI beschreven interactie-studie , waarbij een wederzijdse 
beïnvloeding van diflunisal en amoxycilline - beide onderworpen aan 
actieve tubulaire anion - transport - mechanismen in de nier - in 
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kinetisch gedrag verwacht en gevonden werd. Voor de werking van het 
antimicrobiële middel lijkt zulks geen klinische consequentie 
(effektwijziging, noodzaak van andere dosering) te hebbPn.ae werking 
van het NSAID zou wellicht wat kunnen verminderen (zie tabel II van 
hoofdstuk VI), doch het is met de beperkt voorhanden gegevens zeker 
niet doenlijk tot een advies van geringe dosisverhoging te komen. 
NEVENWERKINGEN VAN DE NSAID 
Naast het reeds op blz. 56 van dit hoofdstuk over bijwerkingen 
gestelde dient te worden aangetekend dat in de gedane trial geen groot 
aantal drop-outs voorkwam. Dit bespaarde ons de noodzaak nader uit 
te werken hoe de gegevens van "resterende" patiënten te hanteren.het-
geen liet moeilijkst zou zijn geweest wanneer in één behandelings-
groep vele patiënten waren uitgevallen. 
Bezien in termen van bijwerkingen-profiel werd volgens verwachting 
bij het salicylzuurderivaat een opvallend aantal C.Z.St.-bijwerkingen 
gevonden (zie tabel III van hoofdstuk IV), welke enige relatie met 
de plasmaconcentratie diflunisal hadden (figuur 3 van hoofdstuk IV). 
Wellicht speelt in het geval van de diflunisal de duur, waarin de 
patient aan een bepaalde plasmaconcentratie (orde van grootte: 
80 mg/l) wordt blootgesteld, een rol bij het tot stand komen van de 
min of meer concentratiegebonden nevenwerkingen; het ontbreken van 
deze nevenwerkingen bij de vrijwilligers in tabel II van hoofdstuk 
VI (Cmin gemiddeld 117 - 140 mg/l; :max gemiddeld 213 - 227 mg/l; 
observatieduur 12 dagen tijdens dosis van 500 mg tweemaal daags) is 
mogelijk deels zo te verklaren. Voorts zou een mogelijk verschil 
in vrije,niet eiwit-gebonden concentratie van diflunisal tussen 
patiënten en (andere) vrijwilligers (met verschillende albuminecon-
centraties:zie tabel I in hoofdstuk VII) verklaring kunnen bieden. 
De in tabel III van hoofdstuk IV gevolgde wijze van presentatie 
van nevenwerkingen (nevenwerking, per patient, per meldingsmoment 
bevattend) geeft een goede mogelijkheid tijdens een trial dit facet 
van de werking van de onderzochte farmaca ook vóór beëindiging van 
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de blinde waarneming bij te houden. Zo kon tijdens de trial (weken 
2, 4, 6, 10, 14, 18, 24) worden afgelezen dat de incidentie van 
gemelde nevenwerkingen (resp. op deze weken 6, 3, 9, 9, 8, 10 en 
6 keer) niet steeg. 
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STELLINGEN 
I 
NSAID bewerkstelligen b i j RA een fract ionele reductie van de afwijkende 
waarden van z iekte-akt iv i te i tsafhankel i jke parameters, mits sprake is van 
nog reversibele afwijkingen. 
(Di t proefschr i f t ) 
II 
Dubbelblinde kl inische t r i a l s b i j RA dienen voor t i j d ig beëindigd te wor-
den, indien het percentage van reductie van z i ek te -ak t i v i t e i t b i j de 
totale t r i a l populatie s igni f icant ongunstig a fw i jk t van eerder met 
het controle-geneesmiddel bereikte resul taten. 
(Dit proefschr i f t ) 
I I I 
Het feit, dat de klinische parameters bij een in de tijd gevolgde groep 
RA patiënten slechts een geringe correlatie tonen en een verschillend 
beloop kunnen hebben, is géén bewijs van armoede van de meetmethodiek, 
doch veeleer een afspiegeling van de grilligheid van de aandoening. 
(Dit proefschrift) 
IV 
Het verdient aanbeveling naasteen minimum aan ziekteaktiviteit als toe-
latingscriterium voor een trial omtrent NSAID bij RA, óók een maximum 
als toelatingsnorm te omschrijven. 
(Dit proefschrift) 
V 
Irreversibele "rest"-schade tengevolge van RA maakt bepaalde parameters 
vrijwel ongeschikt als maten voor een trialgewijze-bestudering van ge-
neesmiddelen bij deze aandoening. 
(Dit proefschrift) 
VI 
De optimale trial-duur ter verkrijging van een oordeel omtrent de waarde 
voor een NSAID als therapeuticum bij RA is beduidend groter dan 2 of 6 
weken. 
(Dit proefschrift) 
VII 
Voor het sterk ondervertegenwoordigd laten zijn van vrouwen in fase I en II 
studies met nieuwe geneesmiddelen, ontbreekt de rationele basis, bovendien 
leidt zulks tot verhoogde risico's in de post marketing fase т.п. t.g.v. 
relatieve overdoseringen. 
E.L. Kinney, Ann.Intern.Med. 1981; 95, 495-499 
Vili 
Adviezen tot het gebruik van megadoseringen (5-9 gram) ascorbinezuur zijn 
zinloos indien resorptie wordt beoogd, gezien de sterk beperkte resorptie 
capaciteit bij de mens voor dit organische zuur. (Eigen waarneming). 
M.Maversohn, Eur.J.Pharmacol. 1972; ID, 140-142. 
Rapportage via tijdschriftartikelen van bijwerkingen door geneesmiddelen 
dient onder redactionele verantwoording te geschieden, temeer nu er 
toetsingsafspraken zijn en worden ontwikkeld voor de bewijsvoering van 
een gemelde bijwerking. 
1. G. van der Kroef.. Ned.Tijdschr. voor Geneesk. 1979;1160-63 
2. C A . Naranjo et al.. Cl in.Pharmacol .Ther., 1981;30,239-245 
X 
Het capsule-lood vormt nu al bij de stijgende wijnconsumptie, een be­
dreiging voor het milieu van + 1000 ton lood per jaar in Nederland. 
Gezien de moderne sealingstechnieken zijn er genoeg alternatieven 
voor een effectieve bescherming tegen de kurkeboorder. 
XI 
De reproductieblokkering bij de wortelluis (Phylloxera vasterix) tengevolge 
van het Nederlandse klimaat, verhindert dat de parasiet een risico voor de 
wijnstok kan vormen. Het kostbare en risico van virus overbrenging dragende 
enten op amerikaanse onderstammen, is daarom een overbodige sanitaire 
maatregel. 
XII 
Hollanditis gaat gepaard met linksverschuiving en overheersen van de 
rode reeks. 
J.W.A. van Loenhout Nijmegen, 18 december 1981. 




